Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery to the nose, trachea, and main bronchi

JP2023534635A5Inactive Publication Date: 2024-12-06SENSORY CLOUD LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023500358
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-31
Filing Date
2021-07-02
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for delivering therapeutic and hygienic agents to the upper respiratory tract are inadequate in preventing the spread of airborne diseases like COVID-19, influenza, and tuberculosis, as they fail to effectively suppress exhaled droplets and bioaerosols, particularly those below 1 μm in size, which conventional masks cannot filter.

Method used

Nasal administration of calcium-enriched saline solutions with droplet sizes ranging from 7 to 15 μm, which interact with airway mucus to enhance viscoelasticity and reduce exhaled aerosols by up to 99%, providing an additional layer of protection against airborne pathogens.

Benefits of technology

The nasal application of calcium-rich saline significantly reduces exhaled particles, including submicron aerosols, enhancing the efficacy of mask-wearing protocols and providing a supplementary defense against respiratory infections by stabilizing the mucus lining and promoting natural immune responses.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Salt-based non-therapeutic hygienic formulations or compositions or therapeutic formulations or compositions (e.g., those rich in calcium) are effective against airborne pathogens and toxins, inhibiting shedding, for example, by increasing the surface viscoelasticity of airway lining fluid. Related devices, methods, and articles are used to deliver salt-based non-therapeutic hygienic formulations or compositions to the upper respiratory tract as a hygienic treatment. Related devices, methods, and articles are used to deliver salt-based therapeutic antibacterial formulations or compositions to the upper respiratory tract. For example, nasal delivery of calcium-rich saline with an aerosol droplet size of approximately 10 μm (e.g., 7 μm to 15 μm, or more preferably 9 μm to 10 μm) can advantageously limit distribution to the nasal and upper respiratory tract and inhibit bioaerosol generation. A nebulizer can deliver the aerosol into free space or into a partially enclosed volume, where the composition is spontaneously inhaled by one or more subjects.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure generally relates to the suppression of exhaled aerosol particles from the upper airways of the human respiratory tract (i.e., nose, pharynx, larynx, trachea and / or main bronchi) via nasally administered salt-based formulations or compositions, for example, calcium-rich salt-based formulations and / or compositions having a mass median diameter (or mass median diameter / mass median diameter) in the range of about 7 microns to about 15 microns, preferably about 10 microns, as well as treatment protocols, devices, and articles suitable for delivery of the salt-based compositions as an aerosol to the nose, trachea, and / or main bronchi of a subject's respiratory tract. [Background technology]

[0002] 2. Description of Related Art Various illnesses are caused by viruses, bacteria, and other inhaled foreign particles. At least some viruses, such as various variations (or variants) of influenza viruses and variations of coronaviruses, are transmitted, at least in part, via respiratory transmission. An example of an airborne bacterial infection is tuberculosis. In one mechanism, a person infected with a microorganism expels the microorganism through disruption of the upper airway lining fluid (or mucus) by breathing, coughing, sneezing, talking, or even singing, potentially exposing others to the microorganism through airborne transmission. The expelled microorganisms can also be drawn deeper into a subject's respiratory tract, such as into the lungs. Inhaled particles from the environment, such as soot particles, can land on the upper airway lining mucus. The dispersal of mucus into respiratory droplets can transport these particles deep into the lungs, promoting allergic reactions and other respiratory diseases. DISCLOSURE OF THE INVENTION [Problem to be solved by the invention]

[0003] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted through the air by large droplets expelled when a person coughs or sneezes and by very small droplets generated in the respiratory tract when a person breathes naturally. How exhaled droplets change between individuals, how they evolve over time within individuals, and how they change during the onset and progression of COVID-19 infection are important for understanding the nature of COVID-19 transmission—and other highly contagious airborne respiratory diseases such as influenza and tuberculosis.

[0004] Delivery of therapeutic substances to the nasal epithelium and other parts of the upper respiratory tract to regulate human health, such as in the delivery of active substances to relieve congestion or symptoms associated with asthma, generally involves the active (forced) delivery of dry or liquid formulations to the nose via sprays, metered-dose inhalers, or dry powder inhalers. The use of these substances to combat infections is generally limited to antibiotics or antivirals. Delivery of pure nasal hygiene substances, such as sodium chloride, to clear mucus is also common. Applicant is not aware of any nasal hygiene specifically targeted against infectious diseases in the way that hand washing or wearing a mask provides protection against infection.

[0005] In the face of an airborne pandemic of the kind posed by COVID-19, our ability to return to normal activities may depend on our ability to provide hygienic protection against airborne infection in the vicinity of the nose, trachea, and major bronchi, where infection often begins and where significant bioaerosol shedding occurs. Such protection may be important from an individual perspective as well as in crowds where, for example, social distancing is not possible. This same hygienic protection may be beneficial for other airborne diseases, such as influenza, and may also be useful in promoting the respiratory health of individuals exposed to high levels of air pollution. [Means for solving the problem]

[0006] Given the potential for widespread disease from inhalation of foreign particles, as evidenced by the ongoing COVID-19 pandemic, new approaches to effectively deliver hygienic and therapeutic agents to reduce respiratory droplet production in the upper airways and thus suppress exhaled droplets or bioaerosols are desirable.

[0007] The generation of respiratory droplets during exhalation can occur due to the force of fast airflow in the upper respiratory tract during breathing, talking, coughing, and sneezing. At peak inspiratory flow during normal breathing, air velocities in the trachea and major bronchi can reach turbulent velocities. The rapid flow of air over the thin (5-10 μm) mucus layer lining the upper respiratory tract can break the mucus surface into small droplets, similar to the breakup of a strong wind and the spray on the surface of the ocean. The nature and extent of this droplet breakup depend on the surface properties of the mucus itself. Among the properties that affect droplet formation and size are surface viscoelasticity (which resists stretching of the mucus surface during breakup) and surface tension (which reduces the energy consumed to generate small droplets). In airway mucus, both properties vary with the type and concentration of lung surfactant, surface particle concentration, and the composition and structure of the mucus adjacent to the air surface. Thus, for example, particle accumulation from breathing polluted air or pathogen growth, or compositional and structural changes in surfactants and mucins driven in part by physiological changes in the human condition, including diet, aging, and the COVID-19 infection itself, can be expected to alter droplet generation and droplet size during the act of breathing.

[0008] The scientific response to the COVID-19 pandemic has primarily focused on developing therapeutic drugs and preventative vaccines. While we await a cure or herd immunity, the scientific community may be encouraged to further focus on managing COVID-19, in part, through reducing respiratory droplet production, as reflected in the number of exhaled particles. In particular, typical masks do not stop all the most numerous airborne submicron particles expelled by infected individuals. For example, approximately 85% of respiratory particles (inhaled and exhaled) are thought to be in the submicron size range. In addition to more effective masks and more refined social distancing rules, approaches that stabilize mucus-lining airways and preserve mucus clearance function would be particularly useful.

[0009] In particular, exhaled aerosol counts are considered to be not only an indicator of disease progression but also a marker of disease risk in non-infected individuals. Diagnostic monitoring is also considered an important strategy to consider in controlling the transmission and infection of COVID-19 and other respiratory infections, including influenza.

[0010] Nasal administration of physiological salts appears to be particularly effective in reducing airborne particles from exhaled breath, including submicron aerosolized particles that are not effectively filtered by cloth face masks. For example, nasal application of drug-free calcium-enriched nasal salts interacts with airway mucus to irrigate the airways of bioaerosols, which can reduce exhaled aerosol particles by up to 99%, with an overall reduction in exhaled particles of approximately 75% in a large cohort of human subjects. Irrigation not only reduces exhalation of particles but can also reduce further inhalation of particles into the respiratory tract (e.g., the lower airways). Nasal administration of physiological salts may be an important addition to current COVID-19 hygiene protocols of mask wearing, hand washing, and social distancing. Nasal administration of physiological salts adds to the efficacy of masks in reducing the penetration of respiratory droplets into the lungs or backflow into the environment, providing an additional layer of defense when wearing a mask is not possible.

[0011] The global crisis caused by the rapid and persistent spread of COVID-19 points to the inadequacy of current defenses against airborne infectious diseases. Nasal administration of physiological salts, particularly calcium-enriched physiological salts, can be used to address the challenges presented to public health by the airborne route of infection and transmission. There is a particular need for a purely hygienic composition and method for clearing the airways of droplets of airway-lining fluid, such as those generated during natural breathing, speaking, coughing, and sneezing. In a study of 10 human volunteers (5 younger than 65 years and 5 older than 65 years), a 5-15 second delivery of nasal saline containing calcium and sodium salts with a mean diameter of 9-10 μm was shown to rapidly (e.g., within 15 minutes) and durablely (e.g., within at least 6 hours) reduce respiratory particles from the human airway without appreciably penetrating the lower airways (i.e., secondary bronchi, tertiary bronchi, bronchi, and terminal bronchi of the lungs) beyond the trachea and primary or main bronchi. Being primarily smaller than 1 μm, these exhaled particles are below the size required for effective filtration by conventional masks. In contrast, in the same study, delivery of a similar calcium-enriched nasal saline solution with droplets of 2–4 μm mean diameter required several minutes to administer and resulted in more uniform suppression of exhaled particles from the human airways, while penetrating beyond the trachea and major bronchi into the lungs. As shown in the same 2004 study, delivery of isotonic saline (sodium chloride) to the lungs via small aerosols (2–4 μm droplets) had a more moderate effect on suppression. In the same study of 10 volunteers, delivery of isotonic saline to the nose via larger droplets ranging from approximately 10 μm to 300 μm with a mean diameter of approximately 40–50 μm had no effect on exhaled aerosols. However, a more recent study showed that delivery of this same aerosol with a similarly large droplet diameter, combined with a head tilt to allow for retronasal instillation, resulted in significant suppression of exhaled aerosols. These results are consistent with known deposition patterns of inhaled aerosols: in particular, droplets in the 1–5 μm range tend to penetrate and deposit throughout the airways, including the alveolar regions of the lungs.Generating a given mass for deep lung delivery with small droplets in this size range requires more energy and therefore more time for a given energy input than generating the same mass for delivery in droplets of, say, 10 μm in size. Inhaled droplets with a diameter of around 10 μm are primarily deposited in the nasopharynx, trachea, and major bronchi. On the other hand, droplets of 15 to 300 μm can be sprayed into the nose, but tend to land there and not penetrate the trachea. Nasally deposited solutions can then drip into the trachea and major bronchi via postnasal drip. While other divalent cations can be delivered to the airways to inhibit respiratory droplet formation, calcium is particularly desirable because it is present in the body at relatively high concentrations. Magnesium is also present in the body, but at low concentrations (approximately 5 to 10 times lower than calcium) and acts more slowly than calcium on negatively charged molecules such as mucin and alginate. Other divalent and multivalent cations may be effective, but are either foreign to the body, as in the case of chitosan, or present in the body, as in the case of iron, while introducing other complex biochemical consequences.

[0012] Suppression of exhaled droplets by nasal delivery of calcium-rich saline with and without sodium chloride and other additives, including lavender, cinnamon, lemongrass, and alcohol, resulted in aerosol droplet median diameters of approximately 7 μm to approximately 15 μm, and preferably approximately 10 μm (e.g., 9 μm to 10 μm), suggesting the upper respiratory tract (i.e., nose, pharynx, larynx, trachea, and major bronchi) as the primary source of bioaerosol generation. The suppressive effect was particularly pronounced among people who exhaled a large number of particles (99%). High particle exhalation appears to correlate with advanced age and body mass index (BMI), as well as with pulmonary infection and long-term exposure to high airborne particulate aerosol loads.

[0013] To complement the widely recommended hand washing with ordinary soap, the use of face masks, and social distancing, a new hygiene practice of "respiratory tract hygiene" using a calcium-rich saline nasal solution is proposed. Respiratory tract hygiene could soon be introduced alongside these other hygiene measures.

[0014] Combinations of hygiene and treatment are also desirable, whether through combinations of salts shown to produce antimicrobial effects or through other therapeutically active substances.

[0015] There is also a need for therapeutic compositions and methods for treating the respiratory tract of individuals known or suspected of having an airborne infection (e.g., COVID-19 infection and other respiratory infections, including influenza), or individuals who have been exposed to other individuals known or suspected of having an airborne infection.

[0016] A new therapeutic practice is described: the nasal application of a calcium-rich saline aerosol, with or without other salts that have been shown to produce antibacterial effects, to the upper respiratory tract, with or without other therapeutically active substances. Nasal application of saline, particularly an aerosol of droplets containing calcium-rich salts (e.g., calcium chloride) with a size restricted primarily to the upper respiratory tract, can advantageously produce antibacterial and / or antipathogenic effects.

[0017] In particular, targeted misters or nebulizers that deliver aerosols with high concentrations of calcium to the upper respiratory tract sites of respiratory droplet formation may be particularly effective. Calcium-rich salt ions may associate with mucin on the mucus-lining surfaces of the airways, enhancing the resistance of mucus to disruption. This can advantageously cleanse the airways of respiratory droplets that can carry infection and insoluble environmental pollutants.

[0018] Alternatively, calcium-rich saline solutions applied to the nose by spray, combined with a head tilted back or reclining position to facilitate post-nasal instillation, is another method for delivering high concentrations of calcium or other polyvalent cationic molecules to the upper airway site of respiratory droplet formation.

[0019] Hygienic and therapeutically active substances are deposited in the nose with varying degrees of efficiency, depending on the nature of the delivery system and technology. This efficiency can be measured as the ratio of the "delivered dose" to the "nominal dose." Delivery of substances to the nasal epithelium occurs in two ways. First, nasal aroma delivery occurs by directly inhaling the airborne substance, for example, through the nostrils or nasal vestibule. Second, post-nasal aroma delivery occurs by natural diffusion and convection of substances in the oral cavity through the oropharynx into the nasal cavity. This latter delivery, called retronasal olfaction, is facilitated by exhalation.

[0020] Described herein are novel salt-based sanitary and / or antimicrobial formulations or compositions that are effective against airborne pathogens and other airborne contaminants, as well as related devices, methods, and articles for the delivery of salt-based antimicrobial and / or anti-infective formulations or compositions. The described salt-based sanitary and / or antimicrobial formulations or compositions, devices, methods, and articles can be advantageously used to inhibit or otherwise reduce aerosol particle shedding of airway-lining fluids (bioaerosols), either on an individual basis or in groups or communities of individuals. The described approach uses a combination of ortho-nasal and retro-nasal delivery, the former occurring upon inspiration of physiological salt solutions and the latter occurring upon expiration of these same salt solutions. The salt-based formulations or compositions are formulated in a readily soluble solution that is applied nasally as a smear or spray, or in the form of aerosolized aqueous droplets having a mass median droplet diameter (MMD) range of about 7 microns to about 15 microns with a standard deviation of less than 5 microns; alternatively, the MMD range is about 9 to about 10 microns, about 9.5 microns, or about 10 microns with a standard deviation of less than 1 micron. These droplet diameter ranges are advantageously too large for significant penetration into the lungs, yet small enough to be transported via the nose to the trachea and major bronchi of the respiratory tract.

[0021] The salt-based hygienic and / or antibacterial preparation or composition may preferably be rich in calcium or magnesium (e.g., calcium chloride or magnesium chloride). Suitable calcium- or magnesium-rich salt-based hygienic and / or antibacterial preparations or compositions may include, for example, salt solutions containing 1%, 2%, 3%, 4%, 5%, 6%, 7%, or 8% CaCl2 or MgCl2; or about 1 to about 10%, about 4 to about 10%, 1.0 to 8.0%, 1.0 to 6.0%, 1.0 to 2.0%, or 4.0 to 6.0% CaCl2 or MgCl2. These CaCl2 or MgCl2 solutions may further contain NaCl, such as 0.1%, 0.5%, 1.0%, or 1.5% NaCl; or solutions containing 0.1 to 1.5%, 0.5 to 1.5%, or 0.1 to 0.5% NaCl. In another embodiment, the salt-based composition does not contain any NaCl in the composition. In another embodiment, the salt-based composition has 0.1 wt% or less NaCl in the composition. The percentages may be wt% based on the total amount of the salt-based composition in a droplet or other amount of salt-containing solution (e.g., water, other solvent). As the examples show, the salt-based component may include 4.72% CaCl and 0.31% NaCl, or 1.29% CaCl and 0.9% NaCl.

[0022] The salt-based solution may also optionally contain one or more preservatives. Preservatives may include any preservative that does not otherwise interfere with the chemical properties of the salt in the salt-based formulation. As one skilled in the art will appreciate, preservatives are on the FDA list of inactive ingredients. Suitable preservatives include benzalkonium chloride, benzyl alcohol, and benzoic acid. Preservatives can be added in amounts known to those skilled in the art, for example, 0.05 to 0.2% by weight, or about 0.1% by weight. Alternatively, or in addition, the salt-based solution may also have a low pH through the addition of HCl or some other means, for example, a pH in the range of about 2 to about 6; alternatively, about 2 to about 5; about 2 to about 3; or about 2.5. HCl acid may be added along with a citrate buffer.

[0023] Alternatively, formulations of CaCl2 with lavender, cinnamon bark, lemongrass, and ethanol, among other essential oils and flavor extracts, have all been effective. Essential oil, fragrance oil, and flavor extract compositions can take any of a variety of forms and can be mixed with water (e.g., distilled or sterile water). For example, start with a 25-milliliter vial of water. Add 0.025 to 1 milliliter of essential oil, fragrance oil, or flavor extract, such as cocoa oil, caramel oil, cinnamon bark oil, coffee oil, eucalyptus oil, palm oil, fig oil, grapefruit oil, hazelnut oil, hazelnut melon oil, lavender or spike lavender oil, lemongrass oil, lime oil, black or green pepper oil, peppermint oil, rosemary oil, strawberry oil, smoke oil, tobacco vanilla oil, vanilla oil, chocolate extract, anise extract, and / or linalool or linalool-containing essential oils. As an example, if the mass of the cloud dispersed in front of the nose is less than 100 milligrams total mass, the total amount of ginger may be less than about 100 micrograms.

[0024] Application can be simple; for example, one or more deep snorts can reduce exhaled aerosols by up to 75%, or even up to 99%, for up to six hours after administration. Protocols for administration can include, for example, application upon arrival at a location (e.g., a work site) before masking. The first application (e.g., two deep snorts) can be administered by a staff member or other individual assigned to a specific task. A second application (e.g., two deep snorts) can follow, for example, during a meal (e.g., lunch) break. The second application can be, for example, self-administered. Self-administration can be performed from a freely accessible wall- and / or table-mounted nebulizer or mister, and can advantageously include a hand sanitizer dispenser mounted or positioned in close proximity to the nebulizer or mister. Alternatively, each individual (e.g., employee) may be provided with a personal nebulizer or mister and an appropriate supply of calcium-rich solution or dry powder to enable the individual to self-administer calcium-rich airway hygiene (e.g., three times daily). Training may be advantageously provided, particularly when self-administration is used.

[0025] Also described herein are various devices that allow for portable, discrete delivery of salt-based sanitary and / or antimicrobial formulations or compositions, increasing the efficiency of delivery to humans and other animals on an individual basis. Advantageously, the devices are configured to be portable, allowing users to have the benefits of on-demand delivery in a wide variety of environments, for example, to suppress viral shedding and / or limit exposure (e.g., deep lung) to undesirable airborne contaminants (e.g., smoke and other airborne toxins).

[0026] Also described herein are various devices that enable mass delivery of salt-based formulations or compositions to groups (e.g., two or more individuals, crowds, processes of individuals) to increase the efficiency of delivery to humans and other animals on a group basis. Such devices can be stationary or portable. Such devices are suitable for use with crowds at stadiums, other venues, and / or various events.

[0027] Additionally, there is a need for diagnostic methods and devices that monitor respiratory droplet emissions from individuals, such as individuals known or suspected of having an airborne disease (e.g., COVID-19 infection and other respiratory infectious diseases, including influenza), or other individuals known or suspected of having an airborne disease, or individuals who breathe contaminated air for extended periods of time. Diagnostic methods can include sampling the subject's exhaled breath, determining a metric characterizing the amount of exhaled droplets shed in the exhaled breath, and correlating the metric with a category indicative of at least one of a level of disease risk and / or a level of contagiousness or infectiousness risk or a level of recommended isolation precautions to be taken. The metric may take the form of, for example, a count or approximate count of exhaled droplets and / or pathogen presence, or another representation of aerosol count. The exhaled breath sampling can be performed over a defined number of exhalations or over a defined period of time. The correlation can be performed with respect to a representative sampling of exhaled breath samples taken from a representative sample of the population.

[0028] Thus, one implementation can be summarized as a composition of aerosol droplets comprising: (a) a salt-based composition comprising about 1% to about 10% by weight of calcium chloride and / or magnesium chloride (e.g., percentage per droplet) in water. The droplets have a mass median droplet diameter ranging from about 7 microns to about 15 microns. In some implementations, the composition of aerosol droplets can include (b1) a preservative selected from the group consisting of benzalkonium chloride, benzoic acid, and benzoyl alcohol, or (b2) an acid in an amount sufficient to lower the pH of the salt-based composition to about 2 to about 6. In some embodiments, either (b1) the preservative or (b2) the acid can be present.

[0029] Another embodiment can be summarized as a composition comprising: (a) a dry powder containing calcium and / or magnesium chloride; and (b) a sterile solution. The sterile solution can consist of water (e.g., sterile water). In some implementations, the water-based composition can include (1) a preservative selected from the group consisting of benzalkonium chloride, benzoic acid, and benzoyl alcohol, or (2) an acid in an amount sufficient to lower the pH of the salt-based composition to about 2 to about 6. The dry powder can be mixed with water or a water-based composition to form the salt-based composition.

[0030] Another embodiment can be summarized as a method of administering a formulation or composition to the nose, trachea, and main bronchi of a subject's respiratory tract. The method includes generating an aerosol of droplets in the nose, trachea, and main bronchi of the subject's respiratory tract within a space that is naturally inhalable by the subject without the application of force. The aerosol of droplets comprises a salt-based composition including calcium chloride and / or magnesium chloride in water, wherein the droplets have a mass median droplet diameter ranging from about 7 microns to about 15 microns.

[0031] Another embodiment can be summarized as a method for suppressing exhalation of particles in the upper respiratory tract of a subject. The method includes generating an aerosol of droplets and administering the aerosol of droplets to the airway lining fluid in the nose, trachea, and main bronchi of the subject, thereby suppressing exhalation of particles in the upper respiratory tract of the subject. The aerosol of droplets includes a salt-based composition including calcium chloride and / or magnesium chloride in water droplets, the droplets having a mass median droplet diameter ranging from about 7 microns to about 15 microns, and the droplets are suspended in a standing cloud.

[0032] Another embodiment can be summarized as a delivery system operable to deliver a purely hygienic or antibacterial formulation or composition to the nose, trachea, and main bronchi of a subject's respiratory tract. The delivery system includes a reservoir having at least one wall at least partially separating the interior of the reservoir from its exterior, the reservoir having a port providing a fluid communication path between the interior of the reservoir and its exterior, the reservoir holding, at least during use, a hygienic or antibacterial formulation or composition comprising a quantity of water and at least calcium chloride and / or magnesium chloride dissolved in the water. The delivery system also includes at least one nebulizer delivery device, the at least one nebulizer delivery device including a reservoir and an actuator, the actuator controllably actuable on an active agent medium to cause the formation of an aerosol comprising readily soluble droplets having a mass median diameter range of about 7 microns to about 15 microns and comprising at least calcium chloride dissolved in the quantity of water.

[0033] Another embodiment can be summarized as a kit for suppressing exhalation of particles in the upper respiratory tract of a subject, the kit including a measured amount of calcium chloride and / or magnesium chloride, a container sized to receive a predetermined amount of water for dissolving the calcium chloride therein, and instructions.

[0034] Another embodiment can be summarized as a method for administering a formulation or composition to the nose, trachea, and main bronchi of a subject's respiratory tract. This method includes generating an aerosol of droplets in a space in the nose, trachea, and main bronchi of the subject's respiratory tract that is naturally inhalable by the subject without the application of force. The aerosol of droplets comprises a salt-based composition comprising calcium chloride and / or magnesium chloride in water. The method for administering a formulation or composition to the nose, trachea, and main bronchi of a subject's respiratory tract is achieved by spraying the salt-based composition into the subject's nose while the subject is in a reclined position with their head tilted back or promoting post-nasal drip.

[0035] Another embodiment may be summarized as a composition of aerosol droplets comprising a salt-based composition comprising: (a) about 1% to about 5% by weight calcium chloride in water; and (b1) a benzalkonium chloride preservative, or (b2) an acid in an amount sufficient to lower the pH of the salt-based composition to about 2 to about 3. Advantageously, this method is not limited by droplet size, although the recited ranges can still be effectively used with this method, e.g., in the 20-30 mg dose range.

[0036] Salt-based non-therapeutic or therapeutic hygienic formulations or compositions (e.g., calcium-rich) are effective against airborne pathogens and toxins, inhibiting their shedding, for example, by increasing the surface viscoelasticity of airway lining fluid. Related devices, methods, and articles are used to deliver salt-based non-therapeutic hygienic formulations or compositions to the upper respiratory tract as a hygienic treatment. Related devices, methods, and articles are used to deliver salt-based therapeutic antimicrobial formulations or compositions to the upper respiratory tract. For example, nasal delivery of calcium-rich saline with an aerosol droplet size of approximately 10 μm (e.g., 7 μm to 15 μm, or more preferably 9 μm to 10 μm) can advantageously limit distribution to the nose and upper respiratory tract and inhibit bioaerosol generation / shedding of pathogens and toxins. A nebulizer or pump with a micron-scale orifice () can deliver the aerosol into free space or into a partially enclosed volume, and the composition can be inhaled (e.g., naturally inhaled by normal breathing) by one or more subjects. [Brief explanation of the drawings]

[0037] In the drawings, identical reference numbers indicate similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes and angles of various elements are not drawn to scale, and some of these elements have been appropriately enlarged and positioned from time to time to improve drawing readability. Furthermore, the specific shapes of elements shown are not necessarily intended to convey any information regarding the actual shape of the particular elements, but have been selected merely for clarity. FIG. 1A is an isometric view of a delivery device for delivering an aerosol of a salt-based sanitary and / or antimicrobial formulation or composition into an unconfined space or volume to be inhaled by a subject, according to at least one illustrated embodiment. FIG. 1B is an illustrative diagram of various sequential actions performed using a delivery device to deliver an aerosol of a salt-based sanitary and / or antimicrobial formulation into either an unconfined or free space or volume, or into a confined space or volume (e.g., a mask, tumbler, glass, vial, beaker, or other container) to be inhaled by a subject, according to at least one illustrated implementation. FIG. 2A is a bar graph showing particles exhaled from two human volunteers prior to administration of a salt-based hygienic and / or antimicrobial formulation or composition that exhibited relatively high viral shedding, according to at least one exemplified implementation. FIG. 2B is a bar graph showing particles exhaled from eight volunteers prior to administration of a salt-based hygienic and / or antimicrobial formulation or composition, according to at least one exemplified implementation, and showing relatively average viral shedding. FIG. 3 is a line graph showing particles exhaled from 10 human volunteers after administration of a salt-based hygienic and / or antimicrobial formulation or composition according to at least one exemplified implementation. FIG. 4A is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4B is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4C is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4D is a graph showing exhaled particles per subject following administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4E is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4F is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4G is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4H is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 4I is a graph showing exhaled particles per subject after administration of a salt-based hygienic and / or antimicrobial formulation or composition compared to a placebo control, according to at least one exemplified implementation. FIG. 5 is a schematic diagram of a portion of a delivery device including a nebulizer that may include a screen and at least one of a piezoelectric element, a solenoid, or an electric motor physically coupled to move the screen, the device also including one or more of a radio, a transducer or sensor, and a switch communicatively coupled to a control system, such as a microcontroller and memory, operably coupled to control operation of the nebulizer according to at least one illustrated embodiment. FIG. 6A is an exploded view of the delivery device of FIG. 5 for delivering a mist, cloud, or aerosol including a salt-based hygienic and / or antibacterial formulation or composition effective against airborne pathogens, according to at least one illustrated embodiment. FIG. 6B is a perspective view of a delivery device for delivering a mist, cloud, or aerosol including a salt-based sanitary and / or antimicrobial formulation or composition that is effective against the airborne pathogens of FIG. 6A, according to at least one illustrated embodiment. FIG. 6C is a side view of a delivery device for delivering a mist, cloud, or aerosol including a salt-based sanitary and / or antibacterial and / or formulation or composition that is effective against the airborne pathogens of FIGS. 6A and 6B, according to at least one illustrated embodiment. FIG. 6D is a cross-sectional side view of a delivery device for delivering a mist, cloud, or aerosol including a salt-based sanitary and / or antimicrobial formulation or composition that is effective against the airborne pathogens of FIGS. 6A-6C, according to at least one illustrated embodiment. FIG. 6E is a side view of components of a delivery device for delivering a mist, cloud, or aerosol including a salt-based sanitary and / or antimicrobial formulation or composition that is effective against the airborne pathogens of FIGS. 6A-6D, according to at least one illustrated embodiment. FIG. 6F is another side view of components of a delivery device for delivering a mist, cloud, or aerosol including a salt-based sanitary and / or antimicrobial formulation or composition that is effective against the airborne pathogens of FIGS. 6A-6D, according to at least one illustrated embodiment. FIG. 7A is a rear view of a printed circuit board and associated components coupled thereto for use in a delivery device for delivering a mist, cloud, or aerosol including a salt-based sanitary and / or antimicrobial formulation or composition effective against the airborne pathogens of FIGS. 6A-6F, according to at least one illustrated embodiment. FIG. 7B is a side view of the printed circuit board and associated components of FIG. 7A according to at least one illustrated embodiment. FIG. 7C is a front view of the printed circuit board and associated components of FIGS. 7A and 7B according to at least one illustrated embodiment. FIG. 7D is a perspective view of the printed circuit board and associated components of FIGS. 7A-7C according to at least one illustrated embodiment. FIG. 7E is a rear view of the printed circuit board of FIGS. 7A-7D without the associated components coupled thereto, according to at least one illustrated embodiment. FIG. 7F is a side view of the printed circuit board of FIGS. 7A-7D without the associated components coupled thereto, according to at least one illustrated embodiment. FIG. 7G is a front view of the printed circuit board of FIGS. 7A-7D without the associated components coupled thereto, according to at least one illustrated embodiment. FIG. 7H is a front view of an alternative configuration of the printed circuit board of FIGS. 7A-7D, without the associated components of FIGS. 7A-7D coupled thereto, according to at least one illustrated embodiment. Figure 8 shows the general design of the protocol for the three study sites, specifically the GRCC study site discussed in the experimental section. Figures 9A, 9B, and 9C show the results for exhaled aerosol particle number and size for 40 human subject volunteers from Bangalore (Figure A), 120 human volunteers from Grand Rapids (Figure 9B), and 93 human volunteers from Cape Cod (Figure 9C). 10A and 10B show the exhaled aerosol counts for 20 subjects 15 minutes after administration of Composition A (FIG. 10A) and several hours after administration of Composition A. Figures 10C and 10D show the inhibitory effect following administration of Composition A versus nasal saline control for total exhaled breath aerosol for all 40 subjects at 2 hours post-dose. Figures 11A, 11B, and 11C compare the effectiveness of nasal saline airway hygiene versus Composition A, as shown by exhaled aerosol from all subjects before and 15-30 minutes after administration of Composition A or plain saline. Results for the 20% highest-emitting aerosol subjects are shown in Figures 11A-C (Composition A). Figures 12A, 12B, and 12C show the degree of overall suppression of exhaled aerosols at each site 15-20 minutes after administration for both Composition A and simple saline. While overall airway lavage with the Simply Saline control was not significant in all cases (BBH p<0.94, GRCC p<0.83, CCA p<0.65), the overall Composition A airway lavage effect was marginally significant at each site tested (BBH p<0.169, GRCC p<0.124, CCA p<0.098). FIG. 13A is a bar graph showing exhaled particle counts from a study of a set of human subjects who presented with mild COVID-19 symptoms prior to treatment according to at least one illustrated implementation. FIG. 13B is a bar graph showing baseline values ​​for human subjects as a function of duration of infection according to at least one exemplified implementation. FIG. 13C is a scatter plot showing baseline values ​​of human subjects as a function of age, according to at least one exemplary implementation. FIG. 13D is a scatter plot showing C-reactive protein levels of human subjects as a function of age, according to at least one illustrated implementation. FIG. 14A is a line graph showing the percentage (%) change in mean exhaled particle count from the corresponding baseline measurement versus time following the baseline measurement for a subset of human subjects following administration of a hypertonic calcium-rich salt targeted to the upper airways of the respiratory tract (FEND), according to at least one exemplified implementation. FIG. 14B is a line graph showing the percentage (%) change in mean exhaled particle count from the corresponding baseline measurement versus time following a baseline measurement for a subset of human subjects after administration of nasal saline spray (simply saline), according to at least one illustrated implementation. FIG. 14C is a line graph showing the percentage (%) change in mean exhaled particle count from the corresponding baseline measurement versus time following a baseline measurement for a subset of human subjects, including an untreated control group, according to at least one exemplified implementation. FIG. 15A is a bar graph showing the percentage of study subjects with high inflammation who required intravenous antibiotic or steroid intervention according to at least one exemplified implementation in a first cohort administered a hypertonic calcium salt (FEND) targeted to the upper airways and a second cohort administered plain saline. FIG. 15B is a bar graph showing the oxygen saturation percentage over the first, second, and third days for: i) a population administered a calcium chloride hygiene and / or antimicrobial formulation or composition; ii) a population administered a sodium chloride (saline) hygiene and / or antimicrobial formulation or composition; and iii) a human control population not treated with a salt-based hygiene and / or antimicrobial formulation or composition, according to at least one example implementation. FIG. 16A is a bar graph showing self-reported symptom scores as a function of days of hospitalization and administration over the first 3 days of FEND, according to at least one illustrated implementation. FIG. 16B is a bar graph showing self-reported symptom scores as a function of days of hospitalization and administration of plain saline as a control over the first three days, according to at least one exemplified implementation. FIG. 16C is a bar graph illustrating self-reported symptom scores as a function of hospital days without administration of nasal salts, in accordance with at least one illustrated embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0038] To provide an appreciation of various embodiments, the disclosure is described in detail below. However, those skilled in the art will readily appreciate that the present invention may be practiced without one or more of these specific details, or with other methods, components, or materials. In other instances, well-known structures related to microcontrollers, piezoelectric devices, Peltier devices, power supplies such as DC / DC converters, wireless radios (i.e., transmitters, receivers, or transceivers), computing systems including client and server computing systems, and networks (e.g., cellular, packet-switched), and other communication channels have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments.

[0039] Unless reason otherwise requires in the specification and claims, the term "comprises" and its derivatives are to be regarded as having an open-ended, inclusive meaning, i.e., "including," but not limited to.

[0040] Throughout the specification, the term "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, all appearances of the phrase "in one embodiment" or "in an embodiment" herein are not necessarily all referring to the same embodiment. Furthermore, particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0041] As used in this specification and the appended claims, the singular includes the plural unless the context clearly dictates otherwise, and the word "or" generally includes "and / or" unless the context clearly dictates otherwise.

[0042] The title and abstract are for convenience only and do not represent the scope of the invention or imply embodiments.

[0043] In particular, described herein are new compositions, systems, methods, and articles for producing one or more salt-based formulations or compositions, particularly calcium-rich physiological salt formulations or compositions, that are advantageously delivered via the nose to the upper respiratory tract to reduce viral shedding and / or as antibacterial and / or anti-infective agents that are effective against airborne pathogens, e.g., to limit exposure (e.g., deep lung) to undesirable airborne pollutants (e.g., smoke and other airborne toxins).

[0044] Nasal administration of physiological salts appears to be particularly effective in reducing airborne particles from exhaled breath, including submicron aerosolized particles that are not effectively filtered by cloth face masks. For example, nasal application of drug-free, calcium-enriched nasal salts interacts with airway mucus to cleanse the airways of bioaerosols, which can reduce exhaled aerosol particles by up to 99%, with an overall reduction of exhaled particles of approximately 75% in the largest cohort of human subjects. Nasal application of physiological salts (e.g., calcium chloride; a combination of calcium chloride and sodium chloride) can, for example, restore the natural surface viscoelasticity of the airway lining fluid and reduce mucus disruption caused by airflow during natural breathing. The majority of these airway droplets are submicron, and as the WHO and CDC recognize them as potential carriers of SARS-CoV-2, their reduction reduces the risk of deep lung infection and disease spread. Nasal administration of physiological salts may be an important addition to current COVID-19 hygiene protocols of mask wearing, handwashing, and social distancing. Nasal administration of physiological salts adds to the effectiveness of masks in reducing the penetration of respiratory droplets into the lungs or back into the environment, adding an additional layer of protection when wearing a mask is not possible.

[0045] In particular, misters or nebulizers that deliver aerosols with high concentrations of calcium to the site of respiratory droplet formation can be particularly effective. Calcium-rich salt ions can associate with mucin on the surface of the airway lining fluid, enhancing the resistance of mucus to disruption. This can advantageously cleanse the airways of respiratory droplets that can carry infection and insoluble environmental pollutants.

[0046] We proposed a new therapeutic practice: intranasal application of calcium-rich saline aerosols to the upper respiratory tract. Nasal application of saline, and in particular, application of aerosols of droplets containing calcium-rich salts (e.g., calcium chloride; combinations of calcium chloride and magnesium chloride; and combinations of calcium chloride and relatively low concentrations of sodium chloride (e.g., 0.1% by weight or less, or completely zero sodium chloride)) with size-restricted droplets primarily to the upper respiratory tract, can produce beneficial antibacterial effects.

[0047] In particular, misters or nebulizers that deliver aerosols with high concentrations of calcium to the upper respiratory tract can be particularly effective. The misters or nebulizers can deliver calcium-rich aerosols with or without other salts that are effective antimicrobial agents and / or with or without other antimicrobial substances.

[0048] These salt-based sanitary and / or antibacterial formulations or compositions are advantageously formulated as or in readily dissolving aqueous droplets. The readily dissolving aqueous droplets have a median size range of about 7 microns to about 15 microns, preferably about 10 microns. Thus, the readily dissolving aqueous droplets are too large to significantly penetrate the lungs, but small enough to be carried to the nasal and upper respiratory tracts of the respiratory tract. Advantageously, such formulations allow the salt-based sanitary and / or antibacterial formulations or compositions to be delivered to the upper respiratory tract without any appreciable delivery to the lower respiratory tract, and can unexpectedly successfully inhibit or otherwise significantly reduce viral shedding. Such formulations can be used to inhibit viral shedding in humans and other animals. Such formulations can additionally or alternatively be used to achieve other beneficial physiological effects, such as limiting exposure (e.g., deep lung) to undesirable airborne pollutants (e.g., smoke and other airborne toxins).

[0049] The droplets are delivered as an aerosol and taken up by the subject, for example, through the act of inhalation. The aerosol can be dispensed (or exhaled) without the use of a closed volume (e.g., a mask, chimney, tumbler, vial, beaker, or other container or vessel), for example, in the open air (e.g., in a room, outside a door), preferably in reasonable proximity to the location of one or more individuals' faces (e.g., positioned relatively in front of one or more subjects' noses). Alternatively, the aerosol can be dispensed into a closed or partially closed volume (e.g., a mask, chimney, tumbler, vial, beaker, or other container or vessel). An individual inhales the salt-based sanitary and / or antibacterial active agent into the upper respiratory tract via the nose, for example, through and / or from the nose, possibly later inhaling the sanitary and / or antibacterial active agent from the nose. Open air distribution may be particularly suitable for treating large crowds, such as crowds entering a stadium or other venue, without individuals in the crowd touching any objects (e.g., delivery devices or dispensers).

[0050] The salt-based sanitary and / or antimicrobial active-loaded droplets described herein can be produced from small reservoirs of less than 100 ml, for example, for individual treatment of subjects. Alternatively, larger reservoirs can be used, for example, when treating crowds of individuals entering a stadium or other venue or event location.

[0051] Salt-based sanitary and / or antimicrobial compositions and formulations may include one, two, or more forms of physiological salts, at least one of which is calcium chloride, dissolved in water. Salt-based sanitary and / or antimicrobial compositions and formulations may include, for example, a combination of calcium chloride and sodium chloride in a 4x isotonic composition (4.72% CaCl2 in 0.31% NaCl) [0.43M CaCl2, 0.05M NaCl]; or a 2x isotonic composition (1.29% CaCl2 in 0.9% NaCl) [0.12M, 0.15M NaCl].

[0052] Salt-based sanitary and / or antimicrobial compositions and formulations may contain one or more other salts, such as potassium chloride and / or magnesium chloride. Salt-based sanitary and / or antimicrobial compositions and formulations may contain, in addition to water, one or more essential oils, aromatic oils, or flavor extracts (e.g., cocoa oil, caramel oil, cinnamon bark oil, coffee oil, eucalyptus oil, palm oil, fig oil, grapefruit oil, hazelnut oil, honey melon oil, lavender or spike lavender oil, lemongrass oil, lime oil, black or green pepper oil, peppermint oil, rosemary oil, strawberry oil, smoke oil, tobacco vanilla oil, vanilla oil, chocolate extract, anise extract, rose oil, and / or linalool-containing oil) and / or solvents (e.g., ethanol).

[0053] Exhaled aerosol counts are considered to be an indicator of disease progression as well as a marker of disease risk in uninfected individuals. Exhaled aerosol monitoring may be performed as a diagnostic technique in the identification and control of transmission and infection of COVID-19 and other respiratory infections, including influenza.

[0054] A new natural defense against airborne pathogens Airborne transmission of infectious diseases via very small droplets expelled from the human respiratory tract during natural breathing and accumulating in poorly ventilated indoor environments has been observed in a range of respiratory diseases, including tuberculosis, measles, chickenpox, influenza, and SARS (Yi et al., 2007). Recent observations place the novel coronavirus SARS-CoV-2, which has been reported to be carried by tiny airborne droplets exhaled by COVID-19 infected individuals and to be stable in aerosol form for more than three hours, similarly placing it within the family of airborne infectious diseases. The assessment of SARS-CoV-2 as an airborne pathogen will shed light on the nature of the fight against the COVID-19 pandemic.

[0055] While major international scientific efforts are underway to develop medicines and vaccines in response to the COVID-19 pandemic, less attention has been paid to new ways to proactively combat airborne viral and bacterial threats. Social distancing, hand washing, and wearing face masks, while effective and necessary, do not prevent the transmission of pathogens that travel through the air in droplets less than 1 μm in diameter. Such tiny particles are not only too small to be effectively filtered by conventional masks, but also too small to settle by gravity within the 2-meter social distancing threshold.

[0056] Submicron droplets, which represent the majority of particles, are expelled from the mouth and nose during natural breathing. Submicron particles leave the respiratory system either through necking of airway lining fluid as the lungs expand and contract, or through the rapid movement of air through the upper respiratory tract that occurs during natural breathing, coughing, sneezing, and speaking. Whether at high or low concentrations in the respiratory tract, tiny droplets expelled from infected lungs can carry viral and bacterial pathogens and toxins into the environment, facilitating the spread of disease. When this expulsion occurs in the upper respiratory tract, it can facilitate the transfer of pathogens and toxins to the deeper lungs, for example, promoting autoinfection.

[0057] Delivery of saline to the respiratory system has been observed to reduce the exhalation of these very small particles. This reduction is due to electrostatic interactions between salt cations and mucin and mucin-like proteins on the surface of the airway lining fluid. These increase the viscoelasticity of the airway lining fluid surface, reducing the formation of airborne droplets. Calcium chloride, much more so than sodium chloride, has been found to increase the surface elasticity of the airway lining fluid, potentially further promoting a more substantial suppression of airborne particle generation in the airways. Meanwhile, the enhanced surface plasticization also further resists pathogen penetration through the mucus layer, strengthening its biophysical barrier against infection.

[0058] Calcium and sodium salts appear to have similar antibacterial properties. High concentrations of extracellular calcium, as can be achieved by aerosol delivery of calcium salts, promote the secretion of β-defensin 2 from nasal epithelial cells. Human β-defensin 2 is an endogenous antimicrobial peptide that binds to the receptor-binding domains of many viruses, including coronaviruses, promoting the expression of antiviral and immune-inducing molecules as well as chemokine recruiters in leukocytes. Human β-defensin 2 has been shown to be effective as an antiviral adjuvant due to its binding to the spike protein of MERS-CoV, and a peptide derived from mouse β-defensin 4 has shown activity against SARS-CoV-1.

[0059] Chloride salts have been shown to reduce viral replication since the 1960s. Chloride ions promote antiviral activity by intracellular induction of hypochlorous acid, the active ingredient in bleach. Chloride salts, in the presence of sodium chloride, induce innate immune responses in epithelial cells. Sodium hypochlorite, the sodium salt of hypochlorous acid, has demonstrated particular efficacy as a disinfectant against coronaviruses. High concentrations of chloride, delivered to the nasal epithelium via hypertonic saline, have been shown to reduce viral infections associated with the common cold. In an open-label, randomized, controlled trial of 68 subjects with common cold infections, including rhinoviruses and coronaviruses, as well as enteroviruses and influenza A viruses, intranasal administration of 2–3% hypertonic saline two to eight times daily (median three times daily) significantly reduced illness duration, over-the-counter medication use, household transmission, and viral shedding. Nasal administration of 3.5% hypertonic seawater has also shown efficacy against common cold symptoms in other human clinical trials.

[0060] Described herein are various salt compositions incorporating at least two ions abundant in human tissue: calcium and chloride, and optionally the tertiary ion sodium, which may be used in hygiene applications, addressing the need for broad-spectrum prophylactic and anti-infective defense against, for example, respiratory viral and bacterial infections. Without being bound by theory, the inventors hypothesized that aerosols combining calcium and, optionally, sodium salts would improve the barrier function of the mucus lining to protect against infection while reducing bioaerosol formation in the lungs and nasal passages. Given the hygiene practice of nasal saline irrigation, nasal delivery of these saline solutions was evaluated in a specially designed nasal mist as a practical, effective, and safe personal hygiene intervention complementary to a mask. This may prove particularly useful for the immediate fight against the current COVID-19 pandemic, but may also be useful against other airborne pathogens and / or toxins.

[0061] result nasal delivery device The handheld nebulizer (Nimbus®) device was designed to deliver a nasal dose of approximately 1–2 mg CalCl of a salt-based sanitary and / or antibacterial formulation or composition. The nebulizer device used an integrated vibrating mesh with a 6 μm pore size to generate an aerosol cloud with an optimal particle size distribution for intranasal delivery through natural nasal inspiration when the device was inverted. The particle size distribution of the aerosol cloud revealed a median volumetric particle size of 9–10 μm, an optimal size for nasal and upper airway deposition of aerosol after natural tidal inspiration through the nose, with a relatively uniform deposition distribution from anterior to posterior of the nose (Calmet et al., 2019). The particle size distribution was significantly smaller than that generated from a standard nasal pump spray (Figure 6B).

[0062] Upon inversion (Figure 1A), the Nimbus® nebulizer device produces 57 mg + / - 2 mg over 10 seconds of activation, after which power is cut off until inversion. The Nimbus® nebulizer device is designed to deliver a controlled dose of approximately 33 mg (i.e., 1.56 mg CalCl2 or 0.43 mg CalCl2) by filling an empty 6 oz. glass with a cloud for an internally programmed 10-second device activation and then inhaling the cloud directly into the nose from the glass (Figure 1B). Uncontrolled dosing can also be achieved by generating a cloud before the nose and direct natural deep nasal inspiration (Figure 1B).

[0063] In comparison to our observations of the effectiveness of salt-based sanitary and / or antimicrobial formulations or compositions for pulmonary delivery, it was decided to follow up a human volunteer study using the Nimbus® nebulizer device to evaluate the effectiveness of salt-based sanitary and / or antimicrobial formulations or compositions for suppressing exhaled aerosol particles after nasal administration.

[0064] Human exhaled breath bioaerosol test: intranasal administration Ten healthy volunteers were recruited from St. Augustine, Massachusetts, Florida, and Boston. Each agreed to participate in a several-hour nasal saline hygiene test. Five were 65 years of age or older (n = 70, 75, 82, 83, and 88), and five were younger than 65 years of age (n = 30, 40, 59, 60, and 63). Subjects with severe respiratory illnesses were excluded from the study, but two of the subjects (n = 30 and 63) were smokers.

[0065] All subjects began the study by breathing into a device measuring exhaled aerosols. Following a baseline assessment of exhaled aerosol particle counts, subjects took two deep nasal inhalations of a 4x isotonic composition of 1.29% CaCl2 and 0.31% NaCl dissolved in water via a Nimbus® nebulizer device. After administration, subjects breathed into an airborne particle detector at intervals up to 6 hours after administration. Subjects also self-administered a commercially available (isotonic sodium chloride) simple saline irrigation spray (CVS Nasal Saline). Following intranasal administration of the placebo control, subjects breathed into an airborne particle detector at intervals up to 2 hours.

[0066] Baseline exhaled particles per liter per subject age are shown in Figures 2A and 2B. Two of 10 subjects in the elderly (>65) group exhaled very high numbers of particles per liter of air (24,088 + / - 9,413 and 7,180 + / - 1,250) (Figure 2A), whereas the other eight subjects (Figure 2B) exhaled approximately 10–1,200 particles per liter. In the latter group, two subjects (aged 30 and 63 years) were smokers. There was a strong correlation between the number of exhaled particles and age, with subjects aged 65 years and older exhaling an average of 6,641 particles per liter and subjects under 65 years exhaling an average of 440 particles per liter. In all subjects, more than 95% of baseline exhaled particles were less than 1 micrometer in size, with the majority being less than 500 nm.

[0067] After administration of the salt-based sanitary and / or antimicrobial formulation or composition, exhaled particle counts decreased for up to several hours, as shown in Figure 3. This decrease, compared to baseline, was statistically significant for all 10 subjects (p<0.05). The duration of the effect continued until the final data point (hours 2-6) after administration for all subjects except for subjects B and E, who were very small particle producers. Administration of the simple saline control had a slight inhibitory effect on exhaled particle counts in two subjects during the first hour after administration, but no inhibitory effect was observed in the other subjects (Figures 4A-4I).

[0068] Using the lowest exhaled particle count after administration as a measure of inhibitory efficacy, bioaerosol reductions ranged from a low of 45% (subject age 75) to a high of 99% (subject ages 83 and 70), with the overall suppression of aerosols in the group (99%) primarily related to the pronounced effect of the aerosolized salt-based sanitary and / or antimicrobial formulation or composition among the super-producing individuals (subject ages 83 and 70).

[0069] Consideration Hypertonic calcium chloride and sodium chloride solutions delivered to the respiratory system appear to have potential as both hygienic and therapeutic biodefenses against airborne pathogens. Hygienic, these physiological salts coat the surface of airway lining fluids to disrupt and remove submicron bioaerosol droplets that are not effectively captured by masks. Potentially by enhancing natural immunological defenses—by strengthening the barrier function of airway lining fluids and promoting the secretion of beta-defensin 2 from nasal and bronchial epithelial tissue—these salts may also act therapeutically for antibiotic prophylaxis or treatment.

[0070] While these results suggest that combinations of calcium and sodium chloride salts may be therapeutically useful against bacterial and viral infections, including influenza, rhinovirus, and pneumonia, these results point to the immediate sanitary value of calcium chloride salt formulations and compositions in the fight against any airborne disease, including COVID-19, by clearing the respiratory tract of tiny airborne infectious droplets that carry airborne infections.

[0071] The finding that in a group of 10 healthy human subjects, nasal inhalation of a salt-based sanitary and / or antibacterial formulation or composition of 1.29% CaCl and 0.31% NaCl dissolved in water reduced exhaled particles by between 45% and 99%, with aerosols too large to penetrate the lower respiratory tract (Figures 8 and 4A-4I), suggests that the upper respiratory tract is the primary source of exhaled bioaerosols. High-velocity airflows generated during natural breathing in the trachea and major bronchi disrupt the surface of airway lining fluid as wind passes over them, creating sea fog. Such phenomena are highly sensitive to compositional variations in the underlying fluid, making exhaled bioaerosols a sensitive measure of airway lining fluid, while introducing intra- and inter-subject variability.

[0072] In this study, application of salt-based sanitation and / or antimicrobial formulations or compositions substantially eliminated exhaled particles, most of which were less than 1 μm in size. The predominance of particles in the 300-500 nm range observed in subjects' exhaled breath can be explained by the fact that such particles are too small to be deposited in the lungs by gravity or inertia, and, once generated, too large to be deposited by diffusion. These are the submicron particles most likely to remain suspended in the air essentially indefinitely. Perhaps most important, in terms of their ability to transmit infection and to deposit on surfaces, including the airways of infected and naive individuals, are particles in the 500-1000 nm range, which represent a significant proportion of superspreader individual exhaled particles. These particles are also substantially eliminated by treatment with salt-based sanitation and / or antimicrobial formulations or compositions.

[0073] In the study, the majority of airborne particles were exhaled by two of the ten "super-producers." This superproduction of bioaerosols promotes the phenomenon of superspreaders (Stein 2015). COVID-19 superspreading events have been reported in China (the so-called Patient 31), India (the Punjab outbreak), South Korea, and many other regions and are suspected to be the primary mode of transmission for the disease. Among the key correlates of superspreading are immune suppression and infected lungs—two particular vulnerabilities of the most elderly. Indeed, the elderly subjects in this study exhaled more particles than younger subjects, suggesting that while they may be most vulnerable to COVID-19 infection, they may also be the subjects most likely to spread the disease, highlighting the extreme risks faced by older adults in nursing homes today.

[0074] As a nasal sanitation treatment, salt-based sanitary and / or antibacterial preparations or compositions are easy to administer (Figure 1B), rapid (one or two deep nasal inhalations), and long-lasting (at least 6 hours in individuals who expel the greatest number of particles). They can be easily administered to individuals in indoor environments where they may encounter others, including hospitals, nursing homes, prisons, schools, offices, factories, stadiums, restaurants, and art schools. The use of salt-based sanitary and / or antibacterial preparations or compositions as an "invisible mask" supplement to traditional masks administered before close encounters with others in public and private spaces to clear the air of small particles that masks do not filter is considered a wise addition to current hygiene practices in the face of the COVID-19 pandemic.

[0075] Further studies could be conducted to evaluate the consequences of calcium-fortified saline nasal sanitation on airborne infection and transmission rates within high-risk settings for COVID-19 and other airborne diseases. The therapeutic potential of these nasally and pulmonary-delivered salts should also be explored beyond the in vitro and animal studies reported herein.

[0076] 1A is an isometric view of a delivery device 100 that delivers an aerosol 102 of a salt-based sanitary and / or antimicrobial formulation or composition into an unconfined space or volume to be inhaled by a subject, according to at least one illustrated implementation. Tipping the Nimbus® nebulizer device against the Earth's gravitational axis activated the actuator, vibrating the mesh and thereby generating the aerosol cloud for administration.

[0077] 1B is an illustrative diagram of various sequential actions performed using a delivery device to deliver an aerosol of a salt-based sanitary and / or antimicrobial formulation to either an unconfined or free space or volume, or to a confined space or volume (e.g., a mask, chimney, tumbler, vial, beaker, or other container or vessel) to be inhaled by a subject, according to at least one illustrated implementation. The salt-based sanitary and / or antimicrobial formulation or composition can be administered by a Nimbus® nebulizer device with deep nose inspiration in an unconfined environment (e.g., by containing the aerosol cloud in a partially enclosed environment such as a mask, chimney, tumbler, vial, beaker, or other vessel or vessel), for example, in an unconfined environment such as in front of the subject's nose.

[0078] As shown in FIG. 1B, a reservoir 104 containing a salt-based sanitary and / or antimicrobial formulation or composition 106 (e.g., CaCl) dissolved in water (e.g., distilled water) is provided at 1. At 2, the reservoir 104 is then coupled to a dispenser portion 108 of a Nimbus® nebulizer device in a generally upright orientation (relative to the axis of gravity). The dispenser portion 108 of the Nimbus® nebulizer device 100 can include a housing, a mesh, an actuator coupled to drivably vibrate the mesh at a desired frequency, and / or a drive circuit. The drive circuit can include, for example, an accelerometer, an earth's magnetic field sensor, a level sensor, and / or a gyroscope, which sense tipping of the Nimbus® nebulizer device relative to the axis of gravity and activate the actuator. The drive circuit can include, for example, a timer that deactivates the actuator after a defined period of time to control the dosage of the salt-based sanitary and / or antimicrobial formulation or composition dispensed.

[0079] In 3, the Nimbus® nebulizer device 100 is positioned adjacent to the subject's face and / or nose 110 and tilted relative to the axis of gravity to dispense (or exhale) the salt-based hygienic and / or antimicrobial formulation or composition as an aerosol 102 into an unrestricted or free space or volume 112 not contained by an enclosure. In response, the drive circuitry activates the actuator to vibrate the mesh, causing the salt-based hygienic and / or antimicrobial formulation or composition to be dispensed as an aerosol adjacent to the subject's nose 110, through the nose 110 (e.g., intranasally) for inspiration by the subject, and into the upper respiratory tract.

[0080] Alternatively, at 4, the Nimbus® nebulizer device 100 is positioned proximate to the opening of a container or vessel 114 and tipped relative to the axis of gravity to dispense the salt-based hygienic and / or antimicrobial formulation or composition as an aerosol 102 into a restricted or at least partially enclosed space or volume at least partially contained by an enclosure (e.g., a mask, chimney, tumbler, vial, beaker, or other container or vessel 114). In response, the drive circuitry activates the actuator to vibrate the mesh and dispense the salt-based hygienic and / or antimicrobial formulation or composition as an aerosol 102 into the container or vessel 114. At 5, the container or vessel 114 is positioned proximate to the subject's face and / or nose 110 for inspiration by the subject through the nose 110 (e.g., transnasally and / or intranasally) and into the upper respiratory tract.

[0081] As used herein, a confined or partially confined or restricted volume is not limited to an unconfined or unrestricted volume (e.g., 100 ft ). 3 or approximately 2.8 m 3 vessel-sized volumes (e.g., 1 ft ) compared to chamber-sized volumes (e.g., 1 ft ). 3 or approximately 28,316 cm 3 This refers to the order of

[0082] Figures 2A and 2B show measurements of exhaled particles from 10 human volunteers before and after salt-based hygienic and / or antibacterial medication. Exhaled particles per liter of air are shown in three size distributions: 300–500 nm, 500–1000 nm, and 1000–5000 nm. In particular, Figure 2A shows results from two of the human subjects (ages 63 and 70), who exhaled over 25,000 and 7000 particles / liter, respectively. The majority of these particles were between 300 and 500 nm, while the majority of particles were between 500 and 1000 nm. Figure 2B shows results from the other eight subjects, who breathed an average of several hundred particles per liter.

[0083] Figure 3 shows measures of exhaled particles from each of 10 human volunteers after salt-based hygienic and / or antibacterial medication. In all cases, the largest "super-productive" subjects (cases 63 and 70) experienced a dramatic reduction in total exhaled particle counts 6 hours after salt-based hygienic and / or antibacterial nasal insufflation of over 99%, while a statistically significant suppression of exhaled aerosols was observed.

[0084] Figures 4A-4I are graphs showing measurements of exhaled particles per subject after salt-based sanitary and / or antimicrobial administration compared to a placebo control. The graphs compare the effects of salt-based sanitary and / or antimicrobial formulations or compositions and isotonic saline (CVS Saline Spray) administration on exhaled aerosol counts. Standard error bars indicate all exhaled particles (all sizes) up to 1 hour after administration. Notably, for the subjects depicted in Figures 4D and 4G, the saline control shows significant suppression, while for the subject depicted in Figure 4F, it shows significant amplification. In all cases, aerosolization treatment with salt-based sanitary and / or antimicrobial formulations or compositions suppresses exhaled aerosol counts compared to the control when comparisons are made between the closest time points of measured counts (p<0.05). The ages of the depicted human subjects are (A) 83, (B) 40, (C) 70, (D) 88, (E) 76, (F) 59, (G) 63, (H) 75, and (I) 30.

[0085] 5 is a schematic diagram illustrating a portion of a nebulizer delivery device 1000 according to at least one illustrated implementation. The nebulizer delivery device 1000 may take the form of or otherwise include a nebulizer 1002 having one or more actuators 1004, and a control subsystem 1006, or other electronics, according to at least one illustrated implementation.

[0086] The nebulizer 1002 can include one or more mesh screens 1008, e.g., metal mesh screens, supported by a frame 1010 for movement, e.g., vibration or oscillation, and can include one or more piezoelectric elements 1012, solenoids 1014, or electric motors 1016 physically coupled to move the mesh screen 1008 along at least one axis in response to signals from a microcontroller to dispense the aerosol into the chamber. In some implementations, the actuators are physically coupled to the mesh screen 1008 via one or more mechanical transmissions (e.g., elliptical gears) or magnetic transmissions. The nebulizer can vibrate the screen, e.g., at ultrasonic frequencies, to cause dispersion of the scent medium. The transducer can oscillate at a frequency of approximately 112 kHz ±10 kHz, sufficient to atomize the fluid held in the fluid reservoir. As will be appreciated by those skilled in the art, the vibration frequency may depend on the geometry and may be tuned to the harmonics of each piezoelectric element design employed as the actuator. The oscillation frequency of such a transducer may be increased or decreased depending on the properties of the fluid or other material held in the fluid reservoir. The fluid may have a viscosity of approximately 1.25 mPa at room temperature, for example. In at least some implementations, the transducer may form an annular ring with a metal mesh contained within a central portion of the transducer. The metal mesh screen 1008 may take the form of various metals, such as stainless steel or 304 or 316 grades, with 316 grade being particularly resistant to corrosion. The metal mesh screen 1008 may be provided as a foil. In some implementations, the metal mesh screen 1008 may be fluidly coupled to the fluid reservoir via a capillary tube, thereby providing a fluid path that allows for low-pressure flow of fluid from the fluid reservoir to the metal mesh screen 1008. Thus, the fluid may be transported, for example, via capillary action, to the metal mesh where it is atomized into a vapor or, more preferably, an aerosol as a result of vibration of the transducer.In some implementations, the metal mesh screen 1008 can provide a filter that prevents larger-sized molecules from being emitted as part of the vapor, or more preferably, the aerosol, exiting the dispenser. Thus, the metal mesh screen 1008 can have mesh openings that are approximately 6 microns in size. In some implementations, the mesh openings can be less than 6 microns in width (e.g., 5 microns, 4 microns, 3 microns, or 2 microns). In some implementations, the mesh openings can be greater than 6 microns in width (e.g., 7 microns, 8 microns, 9 microns, or 10 microns). Preventing larger molecules from being dispensed can provide a better user experience by reducing the likelihood that the vapor, or more preferably, the aerosol, will irritate the user.

[0087] The nebulizer 1002 can include one or more radios 1018 , transducers or sensors 1020 , and switches 1022 communicatively coupled to the control subsystem 1006 .

[0088] The control subsystem 1006 may include, for example, one or more microcontrollers 1024, microprocessors, field programmable gate arrays, and / or application specific integrated circuits. The control subsystem 1006 may include, for example, one or more non-transitory storage media 1026 storing at least one of processor-executable instructions or data that, when executed by the microcontroller 1024, cause the microcontroller 1024 to control the operation of the device 900, for example, in response to one or more inputs. For example, the microcontroller may receive signals from one or more of the radio 1018, the transducer or sensor 1020, and the switch 1022 and, in response, control the operation of the nebulizer 1002. For example, the control subsystem may cause the nebulizer to dispense or disperse a scent medium in response to a first input and cause the nebulizer 1002 to stop dispensing or dispersing a salt-based antimicrobial and / or anti-infective formulation or composition in response to a second input. The input may include user operation of a switch, positioning or orientation of the vessel by a user, or wireless commands from a radio or remote controller.

[0089] The nebulizer delivery device 1000 may include, for example, one or more switches and / or sensors. The switches and / or sensors may be communicatively coupled to the microcontroller and operable to generate a signal that causes the microcontroller to operate the actuator accordingly. The switches may include, for example, any one or more of a contact switch, a momentary contact switch, a rocker switch, etc. The sensors may include, for example, any one or more of the following: the device may include, for example, one or more sensors, such as a one-, two-, or three-axis accelerometer, a PIR motion sensor, an inductive sensor, a capacitive sensor, and a reed switch. The switches and / or sensors may be operable, for example, to generate a signal that causes the microcontroller to operate the actuator in response to at least one nebulizer delivery apparatus 106 coupled to at least one of the docks. The switch (nebulizer) and / or sensor(s) may be operable, for example, in response to the presence or absence of a vessel relative to the base and to generate a signal that causes the microcontroller to operate the actuator depending on the presence or absence of the vessel relative to the base. The switch and / or sensor may, for example, be operable to respond to a position or orientation of the vessel and generate a signal that causes the microcontroller to operate the actuator according to the orientation of the vessel. The switch and / or sensor may, for example, be part of the at least one nebulizer delivery device.

[0090] The nebulizer delivery device 1000 can include a transducer communicatively coupled to operate the nebulizer. The transducer can include, for example, one or more radios (e.g., cellular transceivers, Wi-Fi transceivers, Bluetooth transceivers) that receive wireless signals, such as RF or microwave signals, for one or more wireless communication devices (e.g., smartphones) or remote controllers. The transducer can include one or more receivers, such as, for example, an infrared receiver that receives infrared light signals from a remote controller.

[0091] Activation can be synchronized with the delivery of audio, video, or audiovisual media. For example, a smartphone or digital assistant (e.g., Amazon Alexa®, Google Home®, Apple HomePod®) can trigger activation of the nebulizer 1002.

[0092] A suitable microcontroller may take the form of an 8-bit microcontroller with in-system programmable flash memory, such as the microcontroller commercially available from Atmel Corporation under the designation ATMEGA48 / 88 / 168-AU. The microcontroller executes programs stored in its memory and sends signals to control various other components, such as, for example, valves. The control signals may be, for example, pulse-width modulated (PWM) control signals, particularly when controlling active power supplies. Otherwise, the control signals may take any of a wide variety of forms. For example, the microcontroller may operate a valve or actuator 1004 simply by completing a circuit that provides power to the respective valve or actuator 1004.

[0093] The nebulizer delivery device 1000 can optionally include a visual indicator (not shown) to indicate when the nebulizer delivery device 1000 is operating or turned on. While a single light-emitting diode (LED) may be used, the visual indicator may take any of a variety of forms. The LED may emit one, two, or more nebulizer colors. The visual indicator may also indicate other information or conditions; for example, the visual indicator may flash in response to the occurrence of an error condition. The pattern of flashes (e.g., number of consecutive flashes, color of flashes, number and color of consecutive flashes) can be used to indicate which of several possible error conditions has occurred.

[0094] In some embodiments, the nebulizer delivery device 1000 is motorized by one or more batteries that can provide a power source for the vibration of the actuator 1004. The batteries can be small and lightweight, such as those used in small electronic devices (such as hearing aids). In some implementations, the battery is at least partially embedded within the nebulizer delivery device. In some implementations, the battery is selectively removable and replaceable, such as when the battery no longer provides sufficient charge to operate the nebulizer delivery device 106. Other types of power sources can be provided, such as a power source composed of one or more photovoltaic panels and associated components that can convert light into energy that can be used to operate the nebulizer delivery device 106, an array of supercapacitor or ultracapacitor cells, or an array of fuel cells.

[0095] Although not shown, one or more cartridges can carry the salt-based antimicrobial and / or anti-infective formulation or composition to be dispensed. The cartridges are sized and dimensioned to be removably received by the aroma medium reservoir of the nebulizer delivery device to provide a solution of the salt-based antimicrobial and / or anti-infective formulation or composition to the nebulizer for dispersion, e.g., as droplets or an aerosol spray. The cartridges can be made of plastic. A single-use cartridge can, for example, contain a single dose of the substance to be dispensed and stored in liquid form. Alternatively, a larger reservoir can be used in large venues and events.

[0096] The cartridge can form a fluid reservoir and can be constructed from a polymer, elastomer, or other lightweight, durable material that can be used to hold a liquid. The cartridge can be formed from one or more plastics, such as ABS or polycarbonate plastic. The plastic can be injection molded or vacuum formed to form the cartridge. The type of material or process used to form the cartridge should not be considered limiting. In some implementations, the cartridge can include an internal cavity that forms a fluid reservoir that can be used to hold and contain one or more salt-based antimicrobial and / or anti-infective formulations or compositions, as a fluid or other material (e.g., powder, gel, colloidal suspension) that carries an active agent (e.g., calcium chloride and sodium chloride). In some implementations, for example, the fluid reservoir can be sized and dimensioned to hold up to 100 mL of fluid. In some implementations, the fluid reservoir can be sized and dimensioned to hold a maximum amount of fluid used to form a single dose, e.g., less than 100 mL (e.g., 5 mL, 10 mL, 20 mL, 40 mL, or 50 mL). The fluid can be any liquid or other material that carries or supports a salt-based antibacterial and / or anti-infective formulation or composition, which is released when the fluid transitions to a vapor or, more preferably, an aerosol and is released. The cartridge can include an opening that forms part of a fluid communication path for transferring the fluid from the fluid reservoir to the nebulizer and converting it to a vapor or, more preferably, an aerosol. The vapor, or, more preferably, an aerosol, can advantageously include readily soluble droplets having a median size range of about 7 microns to about 15 microns, more preferably about 10 microns. Thus, the readily soluble droplets are too large to significantly penetrate the lungs, yet small enough to be carried to the upper respiratory tract via the nose.

[0097] 6A-6F show various views of a handheld Nimbus® nebulizer delivery device 2100 for generating and delivering a cloud of aerosolized salt-based antibacterial and / or anti-infective formulation or composition in aerosol form (e.g., a suspension of droplets in air, each containing CaCl and / or MgCl salts in water with or without NaCl at the listed concentrations of droplets).

[0098] The handheld nebulizer (Nimbus®) operates on a vibrating mesh powered by two replaceable AAA batteries. The device consists of a head containing a piezoelectric vibrating mesh and an on / off trigger, and a base or 1 oz. (30 mL) vial that can be filled with a salt-based sanitary and / or antibacterial formulation or composition solution. The Nimbus® vial is removable, made of glass or plastic, filled with sterile solution, and discarded when empty. To assess the delivered dose, a 4-place balance (0.1 mg accuracy) was used with the handheld nebulizer. The Nimbus® was inverted and a cloud was dispensed into a 6 oz. jar covered with a disk with a hole for releasing the cloud into the glass container. After 10 seconds, cloud formation stopped, the Nimbus® was removed, the disk was removed, and the glass was weighed. The "emitted dose" (n=5) results included measuring the entire 10-second release into the jar through the coaster and immediately capping the coaster hole. The total emitted mass from the device was measured to be 57.0±2.1 mg. Approximately 22.1±1.5 mg of the dose was deposited on the glass wall, or approximately 39% of the emitted dose. The nasal delivered dose was evaluated by two users (n=5) who administered a single nasal inhalation from the glass after filling. The results of 22.6 mg and 23.4 mg suggest reproducible delivery of the solution and the range of the target nasal dose, respectively.

[0099] Device 2100 can include any of the forms of any of the other devices described herein and can be used in combination with any of the other devices described herein. As illustrated in FIG. 6A , delivery device 2100 includes base 2102, which can be transparent, which includes a hollow container or tank or vial, in some cases having a volume or capacity of less than 100 mL, for holding the salt-based antimicrobial and / or anti-infective formulation or composition in liquid form. Base 2102 also includes a hollow conduit, tube, or pipe 2116 extending upwardly, through which the salt-based antimicrobial and / or anti-infective formulation or composition can be poured from base 2102 in liquid form. The exterior surface of conduit 2116 includes a set of threads.

[0100] The delivery device 2100 also includes a top or upper or main body 2104 that contains a hollow housing and the electronic and mechanical components of the delivery device 2100. Such components include a printed circuit board 2200 and associated components coupled thereto, a pair of batteries 2106, a hollow conduit, tube, or pipe 2108, a piezoelectric device 2110 that may include or be physically coupled to a mesh screen having a mesh size of 3 microns, 4 microns, 6 microns, 20 microns, or 3-20 microns, as well as an inner cover 2112 and an outer cover 2114 that may be transparent or translucent. The housing of the body 2104 can be opaque or translucent and can have a particular color, such as red, orange, yellow, green, blue, purple, brown, black, or white. The inner cover 2112 can have an appearance that matches the appearance of the housing of the body 2104. In particular, the inner cover 2112 can be opaque or translucent if the housing of the main body 2104 is translucent, and if the housing of the main body 2104 is translucent, the inner cover 2112 can have a particular color that matches that of the housing of the main body 2104, such as red, orange, yellow, green, blue, purple, brown, black, or white.

[0101] Conduit 2108 includes a relatively wide top portion sized to extend around conduit 2116 of base 2102, a relatively narrow middle portion, and a relatively wide bottom portion. The inner surface of the bottom end portion of conduit 2108 includes threads complementary to the threads of conduit 2116 such that conduits 2108 and 2116 may be threadably engaged and thereby coupled to one another. When conduits 2108 and 2116 are coupled to one another, a liquid salt-based antimicrobial and / or anti-infective formulation or composition may be poured from base 2102 through conduit 2116 into conduit 2108. The relatively wide top end of conduit 2108 is sized and configured to accommodate piezoelectric device 2110 at the top end thereof such that the liquid salt-based antimicrobial and / or anti-contamination formulation or composition may flow through conduit 2108, from its lower end, to the piezoelectric device housed in its upper end.

[0102] The conduit 2108 also includes a pair of flanges 2118 coupled to opposing outer surfaces of the central portion of the conduit 2108 and extending laterally outward from each side as well as in a direction aligned with the entire length of the conduit 2108. Each of the flanges 2118 includes a recess or cradle shaped and configured to receive a portion of one of the batteries 2106 to partially confine the batteries 2106 when the device 2100 is assembled. The inner cover 2112 includes a generally circular or disk-shaped main body portion and a hollow, frustoconical portion 2120 extending upwardly from the main body portion. The body portion of the inner cover 2112 includes a pair of openings, i.e., apertures 2122, extending therethrough. Each of the openings 2122 is sized and configured to receive a portion of one of the batteries 2106 to partially confine the batteries 2106 when the device 2100 is assembled. The outer cover 2114 includes a generally circular or disk-shaped main body portion and an opening or aperture 2124 extending therethrough. The opening 2124 is sized and configured to fit snugly around a portion of the outer surface of the cone-shaped portion 2120 of the inner cover 2112 when the device 2100 is assembled.

[0103] 6B, 6C, and 6D respectively illustrate a perspective view, a side view, and a cross-sectional side view of the delivery device 2100. Figures 6E and 6F illustrate two different side views of the delivery apparatus 2100 with the housing of the body 2104 removed to reveal the internal components of the body 2104.

[0104] 7A-7D illustrate the printed circuit board 2200 of the delivery device 2100 along with associated components coupled thereto. FIG. 7A is a rear view of the printed circuit board 2200, showing that the printed circuit board 2200 includes an LED 2202 physically and electrically coupled to its rear surface, the LED being illuminating or operable to illuminate when the delivery device 2100 is generating an aerosolized salt-based antimicrobial and / or antiinfective formulation or composition or a cloud of the salt-based antimicrobial and / or antiinfective formulation or composition in aerosol form, and operable to be off when the delivery device 2100 is not generating an aerosolized salt-based antimicrobial and / or antiinfective formulation or composition. The LED can be useful to a user of the device 2100, as when the LED is illuminating, the user can be confident that power is being supplied to the printed circuit board 2200. 22A also illustrates that the rear surface of the printed circuit board 2200 is physically and electrically coupled to two metal springs 2204, each of which is positioned and configured to act as a contact for and partially support or cradle one of the batteries 2106. One of the springs 2204 can act as a positive contact and the other of the springs 2204 can act as a negative contact for the batteries 2106, thereby placing the batteries 2106 in the device 2100 with opposite polarities.

[0105] FIG. 7B is a side view of printed circuit board 2200, showing that the rear surface of printed circuit board 2200 is also physically and electrically coupled to a plurality of gold pins 2208 to which a fluid sensor can be physically and electrically coupled. FIG. 7C is a front view of printed circuit board 2200, showing that the front surface of printed circuit board 2200 can include an electrical connector 2212, which can be a JST connector, allowing an operator to physically and electrically couple other electronic devices, such as piezoelectric device 2110, to printed circuit board 2200, allowing the printed circuit board and other associated components coupled thereto to communicate with (e.g., send signals to or receive signals from) such other electronic devices, including piezoelectric device 2110. FIG. 7C also shows that the front surface of printed circuit board 2200 is physically and electrically coupled to tilt sensor 2206, which can include an accelerometer or ball tilt switch that connects pins to complete an electrical circuit when the ball moves and device 2100 is tilted, and a plurality of capacitors 2210 for storing electrical energy. Figure 7D is a perspective view of printed circuit board 2200, showing a perspective view of printed circuit board 2200 with associated components coupled thereto. Figures 7E-7G show printed circuit board 2200 without associated components coupled thereto.

[0106] As illustrated in FIGS. 6A-6F, the rear of the printed circuit board 2200, shown directly in FIG. 7A, faces toward the conduit 2108 and the center of the delivery device 2100, while the front of the printed circuit board 2200, shown directly in FIG. 7C, faces away from the center of the conduit 2108 and the delivery device 2100. In some implementations, the printed circuit board 2200 receives power from a power source between 2.0 and 3.4 volts DC and delivers power to a load at 65 volts peak-to-peak at 140 KHz. FIG. 7H shows a front view of an alternative shape and configuration of the printed circuit board 2200. FIGS. 7A-7H show some example dimensions of the printed circuit board 22, using numbers in millimeters. It will be understood that the specific dimensions provided in these figures are merely examples of possible suitable dimensions.

[0107] To operate delivery device 2100, a user can fill base 2102 with the salt-based antimicrobial and / or anti-infective formulation or composition in liquid form, such as by threading or screwing base 2102 onto body 2104, and assemble device 2100 except for battery 2106 and outer cover 2114. The user can then insert battery 2106 into apparatus 2100 through opening 2122 in inner cover 2112 so that the battery is partially resting in a cradle by the recess in flange 2118, and the bottom terminal of battery 2106 makes electrical contact with spring 2204. The user can then couple outer cover 2114 to the rest of apparatus 2100, such as by threading or press-fitting the outer cover onto the top end of body 2104. The underside of the outer cover 2114 can include a strip of conductive material, such as metal, that can engage with the upper terminals of the batteries 2106 and electrically couple the upper terminal of one of the batteries 2106 to the other terminal of the batteries 2106.

[0108] The user can then lift and tilt the device 2100 so that fluid flows, under gravity, from the base 2102 through the conduit 2108 to the piezoelectric device 2110. Once the user tilts the device 2100, for example, to dock with a primary container, the tilt sensor 2206 can generate and transmit a signal indicating that the device 2100 has tilted. Furthermore, once fluid flows into the piezoelectric device 2110, the fluid may contact a fluid sensor coupled to the pin 2208 and generate and transmit a signal indicating that the fluid has reached the fluid sensor. Furthermore, the device 2100 can include a pressure-sensitive switch on its bottom surface, which can generate and transmit a signal that the device 2100 has been picked up when the device 2100 is picked up from a flat surface. In some implementations, the device 2100 does not include a manually operated switch or button and does not receive input from the user other than one, two, or three of the signals described above.

[0109] Upon receiving any one, any two, or all three of such signals, device 2100 can activate piezoelectric device 2110 to begin generating a cloud of aerosolized salt-based antimicrobial and / or anti-infective formulation or composition or salt-based antimicrobial and / or anti-infective formulation or composition in aerosol form from the scent medium in liquid form. Because device 2100 is tilted on its side or upside down, the aerosolized salt-based antimicrobial and / or antimicrobial formulation or composition or cloud of salt-based antimicrobial and / or antimicrobial formulation or composition can flow out of device 2100 through hollow conical portion 2120 and be dispensed into free space to be consumed directly by the user or poured into another container or vessel for subsequent consumption by the user. In some implementations, device 2100 includes an internal timer that automatically turns off or deactivates piezoelectric device 2110 to stop generating a cloud of aerosolized salt-based antimicrobial and / or antiinfective formulation or composition or salt-based antimicrobial and / or antiinfective formulation or composition in aerosol form after a time of about 5, about 10, about 15, or about 20 seconds. In other implementations, device 2100 continues to operate and generate aerosolized salt-based antimicrobial and / or antiinfective formulation or composition or salt-based antimicrobial and / or antiinfective formulation or composition in aerosol form until device 2100 is once again oriented upright or placed back on a flat, horizontal surface.

[0110] Once the fluid in the base 2102 is depleted, the user can remove the base 2102 from the body 2104 of the device 2100, refill the base 2102 with more of the salt-based antimicrobial and / or anti-fouling formulation or composition in fluid form, screw the base 2102 back onto the body 2104, and then resume using the device 100. Once the battery 2106 is depleted, it no longer provides power to the device 2100 and no longer needs to be replaced, the user can remove the outer cover 2114 from the rest of the device 2100, such as by unscrewing, unscrewing, or turning the outer cover 2114 relative to the rest of the device 2100. The old battery 2106 can then be removed within the device 100 and a new battery 2106 installed in its place. The user can then reinstall the outer cover 2114 onto the rest of the device 2100 and resume using the device 2100.

[0111] In some embodiments, the outer cover 2114, or a surface of the rest of the device 2100 that engages with the outer cover 2114, includes a detent that is engaged when the outer cover 2114 is turned relative to the rest of the device 2100 just before the outer cover 2114 is released from the rest of the device 2100. The engagement of the detent can serve as a signal to the user that the outer cover 2114 is about to be released from the rest of the device 2100. When the user releases and removes the outer cover 2114 from the rest of the device 2100, the battery is disconnected and the device is rendered inoperable. The outer cover 2114 can thus act as a switch, where removal of the outer cover 2114 from the rest of the device 2100 turns the device 2100 off, and engagement of the outer cover 2114 with the rest of the device 2100 turns the device 2100 on.

[0112] Alternatively or additionally, the dispenser may use a structure (e.g., a substrate) with one or more nozzles, the nozzles having orifices in the micron size range (e.g., 1 micron to 30 microns). Such nozzles may utilize the Raleigh effect, causing a jet or stream of fluid to pass through an orifice in the micron size range and break up into a monodisperse spray of droplets. The desired droplet size can be achieved by appropriately sizing the orifice, with the droplets typically being twice the size of the orifice. Thus, an orifice size in the range of 3.5 microns to 7.5 microns can achieve a median droplet size in the range of 7 microns to 15 microns, while a 4.5 micron orifice or a 5.0 micron orifice can achieve a median droplet size of 9 microns or 10 microns, respectively. The use of a nozzle with a micron-sized orifice can advantageously reduce variation between droplet sizes in the aerosol, resulting in more uniformity and / or predictability in the amount (e.g., mass) of active substance (e.g., salt) delivered to a subject per unit time. Multiple micron-sized orifices can advantageously increase the number of droplets in the aerosol per unit time. Nozzles with micron-sized orifices can be obtained from MedSpray, Netherlands. The nozzle is implemented as part of a mister with a reservoir and associated pump. Manual activation of the pump can drive fluid from the reservoir through the micron-sized orifice.

[0113] Delivery of aerosols, especially aerosols with fairly consistent droplet sizes, can be advantageous over other forms of delivery (e.g., vapors). Vapors tend to linger longer, stick to surfaces, and are generally more difficult to deliver accurately compared to aerosols. Droplets also typically can retain more mass (e.g., more mass of calcium chloride and / or magnesium chloride) in the vapor, allowing for delivery of an effective dose in a shorter time than via vapor. For example, exposure to an aerosol of droplets with a median size in the 7-15 micron range for less than 1 minute (e.g., 10 seconds) can deliver as much salt as exposure to a vapor of droplets less than 7 microns for several minutes (e.g., 6 minutes). As described herein, control over droplet size can advantageously target the upper respiratory tract, allowing for the effective delivery of smaller amounts of salt compared to delivery not restricted to the upper respiratory tract. Targeted droplet sizes in the 7-15 micron range can advantageously facilitate or enhance retronasal delivery, which can be more efficient than direct nasal delivery.

[0114] Experimental It has recently been observed that delivery of nasal saline consisting of a mist of 10 μm droplets containing a mixture of calcium and sodium chloride salts can reduce respiratory droplets by up to 99% for up to 6 hours after administration. The salts (a hypertonic mixture called Composition A) associate with mucin macromolecules near the mucus surface, binding mucus molecules together and thereby increasing mucus surface tension and surface viscoelasticity. These actions help the mucus surface withstand the stresses imposed by air passing through the mucus during normal breathing, resulting in fewer respiratory droplets in the airways and fewer aerosol particles in exhaled breath. This is a form of "airway hygiene."

[0115] Airway hygiene follows a millennia-old tradition of nasal saline administration to cleanse mucus surfaces of foreign particles. Salts ranging from pure sodium chloride (table salt) at physiological tonicity (0.9% by weight) to more complex mixtures of salts including calcium chloride, magnesium chloride, etc. have long been administered by oral gavage and as nasal sprays. Hypertonic salt compositions can particularly increase ciliary beating, facilitating clearance of mucus and associated particulate matter toward the mouth.

[0116] The impact of airway hygiene was investigated at US learning sites (Grand Rapids, Michigan and Cape Cod, Massachusetts) and compared with a relatively high airborne particle load setting (Bangalore, India). Two intranasal saline administrations (Composition A and plain saline spray) were studied. The findings are reported below.

[0117] method Human volunteer studies were conducted at Bangalore Baptist Hospital (BBH), Grand Rapids Community College (GRCC), and Cape Cod Academy (CCA). IRB approval was received for these (non-drug cosmetic) studies from the BBH Ethics Committee and the GRCC Ethics Committee, and a waiver of the need for IRB approval by an independent, accredited E&I Review was obtained for the CCA study. A total of 440 volunteers were recruited: Bangalore (ages 26-63); 120 volunteers from Grand Rapids (ages 11-68); and 93 volunteers from Cape Cod (ages 10-70). Overall, 126 women, 104 men, and 23 uninformed participants were recruited. Of the 253 human subjects, 82 were Caucasian, 15 were African American, 33 were Asian, 33 were Latino, 49 were Indian, and 41 were unsolicited. Participants were not screened for SARS-CoV-2 infection by serology or polymerase chain reaction (PCR) before enrollment. None of the subjects were known to be COVID-19 positive, but two of the Grand Rapids subjects, a brother (age 16) and a sister (age 19), lived in the same household and were suspected of being asymptomatic carriers based on unusually high exhaled aerosol counts and sibling relationships. All participants in all studies provided written informed consent before enrollment. Figure 8 shows the general design of the protocol for the three study sites (specifically the GRCC study site).

[0118] Before and after intranasal saline administration, exhaled particles were measured using a particle detector (Climet 450-t) designed to count airborne particles in the 0.3-5 micrometer size range. The particle detector was connected to a standard nebulizer tube and mouthpiece, which filtered incoming air through a HEPA filter. Before each subject's first exhaled particle count, each standard nebulizer tube and mouthpiece were removed from their sealed packaging. For subsequent counts, the same mouthpiece, tubing, and HEPA filter were replaced by the participant in the particle counter system to ensure effective hygiene. Subjects took a normal tidal breath through the mouthpiece while blocking their nose over 1-2 minutes, beginning with two deep breaths to empty their lungs of environmental particles. Over this time frame, the particle count per liter decreased to a lower baseline number reflecting particles released from the disruption of the airway-lining fluid surface within the subject's airways. Once the lower particle count plateau was reached, the subject continued breathing normally. Three to eight particle counts (mean particle counts assessed over a 6-second period) were then averaged to determine the mean exhaled particle count and standard deviation. Participants sat opposite the test administrator across a Plexiglas® barrier.

[0119] Two types of saline were used in the study. Composition A was a drug-free nasal saline hygiene formulation consisting of calcium chloride and sodium chloride in distilled water. The total salinity (4x isotonic composition) was in the range of seawater composition, specifically 0.43 M CaCl2, 0.05 M NaCl (4.72% CaCl2, 0.31% NaCl). Composition A was manufactured at Pharmasol (MA) in a GMP mixing and filling facility and contained in a sealed plastic bottle (0.5 oz). The Composition A bottle was opened and emptied into a glass vial in a Mister device. The handheld vibrating mesh nebulizer, manufactured by Perfect Electronics in Shenzhen, China, had a 6 μm pore size and generated an aerosol cloud at the tip of the device with an optimal particle size distribution for nasal delivery through natural nasal inspiration. Producing a median volumetric particle diameter of 9-10 μm (16), optimal for aerosol deposition in the nose and upper airways following a deep, natural nasal inhalation, with a relatively uniform distribution of deposition from the front to the back of the nose, the Nimbus inhales 57 mg + / - 2 mg within 10 seconds of actuation, after which power is turned off until the device is inverted, upright, and inverted again. The device delivers a dose of approximately 33 mg (1.56 mg CalCl2) by filling an empty 6-ounce glass with a cloud for the internally programmed 10-second actuation of the device, then inhaling the cloud directly from the glass into the nose. Dosing can also be achieved by creating a cloud in front of the nose with a deep nasal inhalation.

[0120] A commercially available saline nasal spray, plain saline by Arm & Hammer, was purchased and used as a control (one spray per nostril).

[0121] result Total exhaled aerosol versus ambient inhaled particle mass exposure We assessed exhaled aerosol particle counts and sizes at three locations, including 40 human volunteers in Bangalore (Fig. 9A), 120 human volunteers in Grand Rapids (Fig. 9B), and 93 human volunteers in Cape Cod (Fig. 9C). At each location, a small group of subjects exhaled approximately 80% of the aerosols in the entire group, following the classic 20:80 rule of infectious disease "superspreading."

[0122] "Superspreaders" (of aerosol particles) are considered individuals (though fewer than 20% of all subjects) who exhale 80% of all aerosol particles in a group. Classic superspreader distributions can be found at each US site: at the Grand Rapids site, 79.5% of 120 subjects (20%) generate the group's exhaled aerosols, and at the Cape Cod site, 19 of 93 subjects (20%) generate 79.7% of the group's exhaled aerosols. However, only 10% of subjects in India (4 of 40) generate 82.6% of the group's exhaled aerosols, while 20% of all subjects (8) generate 95.1% of the total exhaled aerosols.

[0123] The skewed importance of high emitters in India reflects the fact that exhaled aerosol counts are dramatically higher in India compared to US sites. The top 20% of aerosol emitters in Bangalore had a mean exhaled aerosol particle count of 30,585 + / - 11,380. Mean exhaled aerosols were statistically lower (p < 0.0002) at US sites, specifically at 532 + / - 668 in Grand Rapids and 818 + / - 722 in Cape Cod. These differences reflect the difference in the burden of suspended particulate matter between Indian and US sites. The reported particle mass <10 µm (PM10) over this same time frame in India (Bangalore) was 150 µg / m3, whereas for US sites, it was an order of magnitude lower (17 µg / m3 in Grand Rapids and 7 µg / m3 in Cape Cod).

[0124] No statistically significant differences were observed between exhaled aerosols at different sites among Caucasian, African American, Asian, Hispanic, or Indian subjects, nor were significant differences observed between subjects of different ages or BMI. A correlation was observed between exhaled aerosols and BMI-in-years (BMI multiplied by age), but the difference in BMI-in-years between the three study sites was not significant.

[0125] Exhaled aerosol versus time after airway hygiene administration The effect of airway hygiene on exhaled aerosols in Bangalore was assessed as a function of time after administration and compared to a saline nasal spray control.

[0126] For subjects receiving Composition A (n=20), exhaled aerosol counts decreased within 15 minutes after administration and remained suppressed for at least 3-4 hours (Figure 10A). For subjects receiving the saline nasal spray control (n=20), exhaled aerosol counts after administration were less severe and remained mixed for several hours after administration (Figure 10B).

[0127] 10C and 10D show the inhibitory effect following Composition A versus nasal saline control on total exhaled aerosol for all 40 subjects at 2 hours post-dose. The large difference in total exhaled aerosol relative to baseline (86%) was highly significant (p<0.011) for Composition A airway hygiene (n=20), while the reduction in total exhaled aerosol (34%) was not significant (p<0.62) for the plain saline control (n=20).

[0128] Suppression of exhaled aerosols through airway hygiene management The effectiveness of nasal saline airway hygiene was evaluated in Bangalore, Grand Rapids, and Cape Cod by assessing exhaled aerosol from all subjects before and 15-30 minutes after administration of Composition A or plain saline. Results for the 20% highest-emitting aerosol subjects are shown in Figures 11A-C (Composition A).

[0129] Composition A administration most significantly reduced exhaled aerosol in the airways of those exhaling the greatest number of aerosol particles at each site, with the most significant % reduction occurring in the most polluted air environments, particularly Bangalore, where exhaled aerosol was most significantly elevated. The non-significant individual subject Composition A suppression compared to baseline seen in Figure 10C versus Figure 11A is associated with a continued decrease in exhaled aerosol with time following Composition A administration (Figure 10A).

[0130] Figures 12A, 12B, and 12C show the degree of overall suppression of exhaled aerosol counts at each site 15-20 minutes after administration for both Composition A and Simple Saline. While overall airway cleansing with the Simply Saline control was not significant in all cases (BBH p<0.94, GRCC p<0.83, CCA p<0.65), the overall airway cleansing effect of Composition A was marginally significant at each site tested (BBH p<0.169, GRCC p<0.124, CCA p<0.098), reflecting the large variance in exhaled aerosol counts between the Low Spreader and Super Spreader (Figures 11A-C).

[0131] Consideration Studies of exhaled aerosols in India and the United States suggest that chronic inhalation of high levels of micron and submicron particulate matter can promote the generation of large numbers of respiratory droplets, distorting these droplets to submicron size (Figure 9). These findings are consistent with the hypothesis that inhaled particles, upon landing on mucus surfaces, reduce surface tension and surface viscoelasticity, making the airway mucosa more susceptible to breakup into smaller droplets.

[0132] These trends have been observed elsewhere in exhaled aerosols after viral (COVID-19) and bacterial (tuberculosis) infections in non-human primates: exhaled aerosols increase and exhaled aerosol particle size decreases in tandem with the growth of viral and bacterial loads in lung tissue.

[0133] Whether the accumulation of viral and bacterial particles on or near mucus surfaces has a similar surface property-altering effect as the accumulation of airborne particulates in the development of respiratory diseases such as COVID-19 and tuberculosis, our findings suggest that the abundance of respiratory droplets plays a role in the spread of airborne diseases in unclean air environments, which may also explain the observed trend of increased COVID-19 mortality risk in polluted environments.

[0134] Airway hygiene is a simple hygienic intervention that can enable people to meet the respiratory droplet carrier challenge wherever they live. Administration of calcium-enriched nasal saline inhibits droplet disruption by increasing surface viscoelasticity through calcium-mucin interactions, cleaning the upper airways of respiratory droplets by up to 99% in the most polluted airways for several hours (Figure 9C). While the effectiveness of airway hygiene is clearly influenced by successful application technique (i.e., deep nasal inhalation), it is significant within 15 minutes of administration (Figure 12) and is remarkably consistent across all sites in all subjects. It is particularly effective in individuals breathing polluted air (Figures 10A and 10C).

[0135] In comparison, the nasal saline spray control had little to no effect, and no overall effect was observed in the short-term (15-30 min) time frame of Figures 12A-C, but was indicative of the effect over time of Figure 10B. This conclusion is consistent with the belief that inhalation of isotonic saline suppresses exhaled aerosols and may suggest that post-instillation drainage of saline from the nose may reach the trachea in some subjects.

[0136] Children and young adults (<26 years of age) have been found to exhale very few particles. Of 120 children and young adults evaluated, only six were observed to exhale 150 particles / L or more, whereas 89% of the younger subjects exhaled 1–50 particles / L of air. Of these six, all exceptions exhaled aerosols exceeding 1,000 particles per liter. In three of these cases, subjects 5, 8, and 39 from our Bangalore study, the young subjects inhaled highly contaminated air into their respiratory tracts. In two of the cases, siblings (aged 16 and 19) from Grand Rapids, the children were suspected of being asymptomatic carriers of COVID-19, but in one case, a 17-year-old male from Cape Cod, no apparent causal role for airway particle burden was observed. Young people, as a rule, have few respiratory droplets, but they can be high producers of respiratory aerosols, and their airways in particular should be covered by foreign bodies, whether they be embedded particulate matter or, as in the case of infectious diseases, multiplying viruses.

[0137] While a combination of environmental and biological factors clearly makes some individuals more susceptible than others to respiratory disease and airborne transmission, including COVID-19, the results suggest that inhaled particles themselves may be the source of excessive respiratory droplet production and the risk of infection and transmission, by weakening airway lining fluids. 313±145 ago After 15±27

[0138] These results show that before administration of Composition B, individuals exhaled 313±145 particles per liter, and 30 minutes after administration of Composition B, individuals exhaled 15±27 particles per liter, demonstrating the effectiveness of Composition B.

[0139] Bangalore Study Details A randomized, controlled, two-arm trial was conducted in Bangalore, India to evaluate whether saline hydration of the upper respiratory tract reduces symptoms of the delta variant of COVID-19.

[0140] Salt delivered to the upper airway increases upper airway hydration and reduces respiratory droplet generation. It was hypothesized that this salt-mediated reduction in respiratory droplet production might slow the progression of pathogens such as SARS-CoV-2 to the lower respiratory tract and reduce symptoms in patients with mild symptomatic COVID-19, regardless of the nature of the pathogen.

[0141] method This randomized, single-blind, nasal saline-controlled trial evaluated the effect of daily administration of calcium-rich hypertonic salts to the upper airway on exhaled aerosols and COVID-19 symptoms during the period (December 2020 to June 2021) during which the Delta (B.1.617.2) coronavirus variant emerged as the primary cause of infection in Bangalore. The study recruited 84 human volunteers from mildly symptomatic COVID-19 patients. Participants were screened for SARS-CoV-2 infection by polymerase chain reaction (PCR) before enrollment. IRB approval for this study was obtained from the Ethics Committee of Bangalore Baptist Hospital. All participants provided written informed consent before enrollment. In this study, symptoms were assessed immediately after enrollment using blood analysis (C-reactive protein, d-dimer), lung X-ray, oxygen saturation, body temperature, and self-reported symptoms (fever, cough, diarrhea, loss of taste / smell, difficulty breathing, and body aches). All participants' exhaled particles were measured using a particle detector (Climet 450-t) designed to count airborne particles in the size range of 0.3 μm to 5 μm or larger. Of the enrolled COVID-19-positive patients, all participated in exhaled aerosol measurements, and 39 were randomly assigned to two multi-day treatment cohorts. The active (FEND) cohort of 20 subjects received nasal inhalation of a calcium-rich hypertonic saline solution (0.43 M CaCl2, 0.05 M NaCl) (4.72% CaCl2, 0.31% NaCl) via a handheld vibrating mesh nebulizer with a median volume droplet diameter of 9–10 μm, designed to target the nose, trachea, and main bronchi. The control (A) cohort of 19 subjects received saline (0.9% sodium chloride) via nasal spray three times daily for the first three days after admission to the study. Patients received the active and control medications three times daily for the first three days after admission to the study and were blinded to the active and control medications. Exhaled aerosol was assessed for all active and control subjects before and after saline administration, and exhaled aerosol was monitored for two hours after delivery.All patients were monitored daily for oxygen levels, temperature, intravenous antibiotic and steroid treatment (if needed), and self-reported symptoms on a scale of 1 to 5 (ascending from no symptoms to most severe symptoms). Patients with symptoms severe enough to require escalation to intensive care within the first 3 days of admission were excluded from the study. Statistical significance of differences in variables was calculated using multiway analysis of variance (ANOVA) tests and Student's t-tests.

[0142] findings As the delta variant of the SARS-CoV-2 virus spread in Bangalore, India, becoming the predominant strain sequenced, studies measured an increase in mean exhaled droplet counts among 83 COVID-19-positive patients from 1468 + / - 1883 particles per liter of air between December 2020 and February 2021 to 8234 + / - 4315 particles per liter of air in early June 2021. In a randomized, controlled, two-arm trial at Bangalore Baptist Hospital, administration of hypertonic calcium and sodium salts (FEND) to the upper airways of 39 patients reduced respiratory droplet production by 42.72% + / - 30.51% (P = 0.014), whereas no reduction was observed 60 minutes after baseline in patients receiving a nasal saline control (Simply Saline) (P = 0.39). Participants with severe inflammation (CRP levels >10 mg / L) required daily intravenous antibiotic or steroid intervention for 3 days, compared with 93% in the Simply Saline group and 55% in the FEND group. Oxygen saturation significantly increased in the FEND group (P = 1.86e-8), whereas no significant increase in oxygen saturation levels was observed in the Simple Saline group (P = 0.128). Self-reported symptom scores decreased by 55.44% ± 7.43% in the FEND group, whereas self-reported symptoms decreased by 32.18% ± 7.91% in patients receiving the nasal saline spray control. 61% of patients in the FEND group were discharged asymptomatic, compared with 0% in the nasal saline group.

[0143] interpretation Daily delivery of calcium-rich salts to the upper respiratory tract reduces the need for anti-inflammatory steroid and antibiotic treatment, increases oxygen saturation, and reduces COVID-19 symptoms in mildly symptomatic patients infected primarily with the Delta variant compared with an isotonic saline control. The results suggest that daily administration of a non-drug saline solution to the upper respiratory tract may be a useful hygiene measure to reduce the severity of COVID-19 symptoms, regardless of the nature of the COVID-19 variant.

[0144] preface Rapid mutations and challenges with access to vaccination are prolonging the COVID-19 pandemic in low-income regions of the world, threatening human populations. A non-pathogen-specific hygiene approach to airborne respiratory diseases, comparable to hand hygiene for gastrointestinal infections, could potentially save lives during the current global pandemic and improve respiratory health post-pandemic in light of deteriorating air quality.

[0145] Upper airway hydration appears to reduce the risk of airborne infections through various mechanisms, including increased cilia beating frequency and reduced upper airway production of respiratory droplets, which have been identified as a primary vector for SARS-CoV-2 transmission. Nasal administration of a hypertonic mist of divalent calcium and magnesium salts with a median droplet size of 9–10 μm appears to be a particularly effective means of upper airway hydration, reducing respiratory droplet production for 4–6 hours after administration compared with approximately 1 hour after breathing humid air or wearing a mask. Inhalation of a mist of 9–10 μm droplets targets the hypertonic salts to the trachea and major bronchi, where primary hydration of the incoming air occurs. This non-drug hydration approach clears the airways of respiratory droplets and potentially reduces the migration of inhaled pathogens (and other contaminants) deposited in the upper airways to the deep lung, where they can promote severe symptoms, regardless of pathogen type.

[0146] Applicant hypothesized that in human subjects infected with COVID-19, nasal administration of calcium-rich hypertonic saline into the upper respiratory tract three times daily may significantly reduce symptoms in recently infected, mildly symptomatic subjects and may be an effective non-drug strategy against highly contagious variants of SARS-CoV-2, including the delta variant (B.1.617.2), which first emerged in India in October 2020. To explore this hypothesis, this study recruited hospitalized COVID-19-positive patients at Bangalore Baptist Hospital from December 2020 to June 2021, paralleling the recent surge in infections fueled by the spread of deltacoronavirus variants. The study assessed exhaled aerosols from all volunteers and enrolled a subset of volunteers in a randomized, controlled, two-arm trial, as reported in this paper.

[0147] method Study design and participants This study recruited 84 volunteers, aged 16–57 years, from mildly symptomatic COVID-19 patients at Bangalore Baptist Hospital (BBH) during the pandemic in India (December–June 2021). During this period, sequencing of BBH infections with the delta (B.1.617.2) coronavirus variant increased from a small number of cases to 70% of infections in India (14). Participants were screened for SARS-CoV-2 infection by polymerase chain reaction (PCR) before enrollment. IRB approval for this study was obtained from the Ethics Committee of Bangalore Baptist Hospital. All participants provided written informed consent before enrollment. Symptoms of all 84 participants were assessed immediately after enrollment by analysis of blood markers of inflammation (CRP, d-dimer), lung X-rays, pulse oximetry, temperature, and self-reported symptoms (fever, cough, diarrhea, loss of taste / smell, dyspnea, and body aches). All participants' exhaled particles were measured using a particle detector (Climet 450-t) designed to count airborne particles in the size range of 0.3 μm to ≥5 μm. Thirty-nine participants were randomly assigned to two treatment cohorts. The active (FEND) cohort of 20 subjects received nasal inhalation of a calcium-rich hypertonic saline solution (0.43 M CaCl2, 0.05 M NaCl) (4.72% CaCl2, 0.31% NaCl) via a handheld vibrating mesh nebulizer with a median volume droplet diameter of 9–10 μm, designed to target the nose, trachea, and main bronchi. The control cohort of 19 subjects (A) (simple saline) received intranasal spray of saline (0.9% sodium chloride). All participants received either the active or control treatment three times daily for the first three days of the study. Patients were blinded to whether they received the active or control treatment. In this study, exhaled aerosol was assessed in all active and control patients before and after salt administration, and exhaled aerosol was monitored for 1 to 2 hours after delivery. All patients were monitored daily for oxygen saturation, temperature, intravenous antibiotic and steroid treatment (if needed), and self-reported symptoms on a 1 to 5 scale (ascending from no symptoms to most severe symptoms).Patients who required supplemental oxygen before admission or during the first 3 days after admission (blood oxygen saturation <95%) were excluded from the study.

[0148] procedure Exhaled particles were measured before and after administration of the active substance or control using a particle detector (Climet 450-t) designed to count airborne particles in the size range of 0.3 μm to over 5 μm. The particle detector air port was attached (via a T-connector) to the side of a 1" inner diameter tube through which the subject inhaled and exhaled using flexible plastic tubing. The 1" tube was connected to a mouthpiece with standard nebulizer tubing at one end and a portable HEPA filter at the other end. The entire tubing system facilitated filtration of all environmental particles from the subject's lungs while the subject tightly sealed their lips around the mouthpiece and breathed with their noses pinched for approximately 1 minute. The particle counter flow rate (50 L / min) was near the peak inspiratory / expiratory flow rate typical of human subjects' breathing, ensuring that the direction of airflow remained in the particle counter. Before each subject's first exhaled particle count, each standard nebulizer tube and mouthpiece were removed from their sealed packaging. For subsequent counting procedures, the same mouthpiece, tubing, and HEPA filter were reattached by the participant to ensure the absence of contamination from one subject to the next. Before each test, the mouthpiece was replaced with a stopper and the particle detector was turned on to confirm the absence of particle leakage from the environment. A count of 10 particles or less per liter of air was considered "sealed," and the mouthpiece was replaced with the tubing. The subject then took normal tidal breaths through the mouthpiece while blocking their nose with their fingers for 1-2 minutes, starting with two deep breaths to clear their lungs of environmental particles. Over this time frame, the particle count per liter of air drawn into the particle counter from exhalation decreased and subsequently fluctuated around the baseline count. Taking into account the external environment, the tight lip seal, and ensuring the absence of leakage from the pinched nose, we assumed this baseline count was equal to the particles generated within the subject's airway. Subjects who reached a lower plateau of particle counts continued breathing normally for determination of exhaled aerosol particle counts. Participants sat opposite the study administrator across a Plexiglas® barrier.The Climet 450-t particle counter reports particle counts as a function of aerodynamic particle size range for particles greater than 0.3 μm, particles greater than 0.5 μm, particles greater than 1 μm, and all particles greater than 5 μm. The reported numbers represent the average particle counts measured automatically over a 6-second period by the light scattering detector. For the determination of exhaled aerosol particle counts, the study averaged three to eight particle counts (each integrating a 6-second interval) as reported by the particle detector to determine the mean exhaled particle count and standard deviation.

[0149] Blood samples were taken and tested (i.e., C-reactive protein (CRP), D-dimer) to detect Covid-19. Oxygen saturation levels were measured by pulse oximetry. Patients with high levels of inflammation and concomitant symptoms received intravenous antibiotics or intravenous steroids. If oxygen levels fell below prescribed levels, patients were escalated to intensive care and removed from the study.

[0150] result The primary outcomes were exhaled aerosol particle count, need for intravenous antibiotics or anti-inflammatory steroids, and oxygen saturation. Secondary outcomes were daily self-reported symptom scores. Data from this study are presented in Figures 13A, 13B, 13C, 13D, 14A, 14B, 14C, 15A, 15B, 16A, 16B, and 16C.

[0151] statistical analysis All error bars represent 95% confidence intervals based on standard deviation values. The significance of differences between individual and collective aerosol counts was determined by a two-tailed T-test. Statistical significance of differences was calculated using a multiway analysis of variance (ANOVA) test for each set of variables, allowing for evaluation of the influence of multiple factors on the mean within a 95% confidence interval. P values ​​were calculated for each unique set of variables compared to baseline values. P values ​​less than 0.05 were considered statistically different.

[0152] 13A shows a bar graph of exhaled particle counts from a study of a set of human subjects who presented with mild COVID-19 symptoms prior to treatment according to at least one exemplified implementation. Specifically, exhaled particles were collected prior to application of calcium chloride aerosol with droplets having a median droplet size of about 10 microns for one cohort, and prior to application of sodium chloride (saline) aerosol with droplets having a median droplet size of about 10 microns for another cohort.

[0153] 13B shows a bar graph of the baseline mean exhaled particle counts of human subjects in the study as a function of duration of infection, according to at least one exemplified implementation. Error bars represent the standard error of the mean.

[0154] FIG. 13C shows a scatter plot of baseline values ​​for mean exhaled particle count for human subjects as a function of age according to at least one exemplified implementation.

[0155] FIG. 13D shows a scatter plot of C-reactive protein levels of human subjects as a function of age according to at least one illustrated implementation.

[0156] FIG. 14A shows as a line graph the percentage (%) change in mean exhaled particle count from the corresponding baseline measurement versus time following the baseline measurement for a subset of human subjects following administration of a hypertonic calcium-rich salt targeting the upper airways of the respiratory tract (FEND), according to at least one exemplified implementation.

[0157] FIG. 14B shows as a line graph the percentage (%) change in mean exhaled particle count from the corresponding baseline measurement versus time following the baseline measurement for a subset of human subjects after administration of nasal saline spray (simply saline), according to at least one exemplified implementation.

[0158] 14C shows as a line graph the percentage (%) change in mean exhaled particle count from the corresponding baseline measurement versus time following the baseline measurement for a subset of human subjects, including an untreated control group, according to at least one exemplified implementation. The untreated group was not treated with hypertonic calcium-rich salts targeting the upper airways (FEND) of the respiratory tract, and was not treated with nasal saline spray (simple saline).

[0159] 15A shows a bar graph of the percentage of study subjects with high inflammation who required intravenous antibiotic or steroid intervention in a first cohort administered a hypertonic calcium salt targeting the upper airways (FEND) and a second cohort administered plain saline, according to at least one exemplary implementation. The first cohort administered a hypertonic calcium salt targeting the upper airways (FEND) included 9 of 20 subjects. The second cohort administered saline included 9 of 19 subjects.

[0160] Figure 15B shows bar graphs of oxygen saturation percentages over the first, second, and third days for: i) a population administered a calcium chloride hygiene and / or antimicrobial formulation or composition; ii) a population administered a sodium chloride (saline) hygiene and / or antimicrobial formulation or composition; and iii) a human control population not administered a salt-based hygiene and / or antimicrobial formulation or composition. Error bars represent the standard error of the mean.

[0161] 16A shows a bar graph of self-reported symptom scores as a function of days of hospitalization and administration over the first three days of FEND, according to at least one exemplified implementation. Self-reported symptom scores are reported on a scale of 1 to 5, with 1 = no symptoms and 5 = most severe symptoms.

[0162] 16B shows a bar graph of self-reported symptom scores as a function of days of hospitalization and administration of plain saline as a control over the first three days according to at least one exemplified implementation. Self-reported symptom scores are reported on a scale of 1 to 5, with 1 = no symptoms and 5 = most severe symptoms.

[0163] 16C shows a bar graph of self-reported symptom scores as a function of hospital days without administration of nasal salts, according to at least one illustrated embodiment. Self-reported symptom scores are reported on a scale of 1 to 5, with 1 = no symptoms and 5 = most severe symptoms.

[0164] Example Example 1: 1. A composition of an aerosol of droplets comprising a salt-based composition, wherein each droplet comprises: about 1% to about 10% by weight of calcium chloride and / or magnesium chloride in water; The composition, wherein the droplets have a mass median droplet diameter in the range of about 7 microns to about 15 microns. Example 2: The composition of example 1, wherein the droplets comprise more than 1% by weight of calcium chloride and / or magnesium chloride. Example 3: The composition of example 1, wherein the salt-based composition is free of sodium chloride or contains 0.1% or less by weight of sodium chloride. Example 4: 4. The composition of any of Examples 1-3, wherein the salt-based composition further comprises an essential oil, aromatic oil, or flavor extract selected from the group consisting of cocoa oil, caramel oil, cinnamon bark oil, coffee oil, eucalyptus oil, palm oil, fig oil, grapefruit oil, hazelnut oil, honey melon oil, lavender or spike lavender oil, lemongrass oil, lime oil, black or green pepper oil, peppermint oil, rosemary oil, strawberry oil, smoke oil, tobacco vanilla oil, vanilla oil, chocolate extract, anise extract, rose oil, linalool-containing oil, and combinations thereof. Example 5: The composition of any of Examples 1 to 3, wherein the salt-based composition comprises calcium chloride and / or magnesium chloride and at least 10% by weight of ethyl alcohol. Example 6: The composition of any of Examples 1 to 3, wherein the droplets comprise about 4% to about 10% by weight of calcium chloride and / or magnesium chloride. Example 7: The composition of any of Examples 1 to 3, wherein the droplets comprise about 1% to about 5% by weight of calcium chloride and / or magnesium chloride. Example 8: The composition of any of Examples 1-3, wherein the droplets have a mass median droplet diameter in the range of 9 microns to 10 microns. Example 9: The composition of any of Examples 1-3, wherein the droplets have a mass median droplet diameter of about 9.5 microns with a standard deviation of less than 1 micron. Example 10: The composition of any of Examples 1-3, wherein the droplets have a mass median droplet diameter in the range of 7 microns to 15 microns with a standard deviation of less than 5 microns. Example 11: The composition of any of Examples 1 to 3, wherein the majority of the droplets have a droplet size between 9 microns and 10 microns in diameter. Example 12: The composition of example 11, wherein the majority of the droplets have a droplet size of about 9.5 microns in diameter. Example 13: The composition of any of Examples 1-3, wherein the salt-based composition comprises a preservative selected from the group consisting of benzalkonium chloride, benzoic acid, and benzoyl alcohol. Example 14: The composition of example 13, wherein the preservative is benzalkonium chloride. Example 15: The composition of example 14, wherein the benzalkonium chloride is present in an amount ranging from about 0.05% to about 0.2% by weight. Example 16: The composition of any of Examples 1-3, wherein the salt-based composition comprises an acid in an amount sufficient to lower the pH of the salt-based composition to about 2 to about 6. Example 17: The composition of Example 16, wherein the pH is in the range of about 2 to about 3. Example 18: The composition of example 15, wherein the acid is citric acid, hydrochloric acid, or a combination thereof. Example 19: 3. The composition of any one of Examples 1 to 2, wherein the salt-based composition comprises about 1.0% to about 6.0% by weight of calcium chloride and about 0.1% to about 1.5% by weight of sodium chloride. Example 20: The composition of example 19, wherein the salt-based composition comprises about 1.0% to about 2.0% by weight of calcium chloride and about 0.5% to about 1.5% by weight of sodium chloride. Example 21: The composition of example 19, wherein the salt-based composition comprises about 4.0 to 6.0 wt. % calcium chloride and about 0.1 to about 0.5 wt. % sodium chloride. Example 22: (a) a dry powder containing calcium chloride and / or magnesium chloride, and (b) a sterile solution of a water-based composition, (1) a preservative selected from the group consisting of benzalkonium chloride, benzoic acid, and benzoyl alcohol; or (2) a sufficient amount of acid to lower the pH of the salt-based composition to about 2 to about 6; A sterile solution of the water-based composition comprising: wherein the dry powder is capable of being mixed with the water-based composition to form a salt-based composition. Example 23: The composition of example 22, wherein the water-based composition comprises a preservative selected from the group consisting of benzalkonium chloride, benzoic acid, and benzoyl alcohol. Example 24: The composition of example 23, wherein the preservative is benzalkonium chloride. Example 25: The composition of example 22, wherein the water-based composition comprises the acid in an amount sufficient to lower the pH of the salt-based composition to about 2 to about 4. Example 26: The composition of example 22, wherein the pH of the salt-based composition ranges from about 2 to about 6. Example 27: The composition of Example 26, wherein the pH ranges from about 2 to about 5. Example 28: The composition of example 25, wherein the acid is citric acid, hydrochloric acid, or a combination thereof. Example 29: The composition of example 22, wherein the dry powder contains no sodium chloride or less than 0.1% by weight of sodium chloride. Example 30: The composition of example 22, wherein the dry powder is in a sachet. Example 31: 1. A method of administering a formulation or composition to the nose, trachea, and main bronchi of the respiratory tract of a subject to inhibit viral shedding, comprising: generating an aerosol of droplets in a space, the aerosol being naturally inhalable by the subject without exerting any force on the nose, trachea, and main bronchi of the airway of the subject; the aerosol of droplets comprises a salt-based composition comprising calcium chloride and / or magnesium chloride in water; The method wherein the droplets have a mass median droplet diameter in the range of about 7 microns to about 15 microns. Example 32: 32. The method of example 31, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, the droplets comprising greater than 1% by weight of calcium chloride and / or magnesium chloride. Example 33: 32. The method of example 31, wherein generating an aerosol of droplets comprises generating an aerosol of droplets wherein the salt-based composition is sodium chloride-free or contains 0.1% or less by weight of sodium chloride. Example 34: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets wherein the salt-based composition further comprises an essential oil, aromatic oil, or flavor extract selected from the group consisting of cocoa oil, caramel oil, cinnamon bark oil, coffee oil, eucalyptus oil, palm oil, fig oil, grapefruit oil, hazelnut oil, honey melon oil, lavender or spike lavender oil, lemongrass oil, lime oil, black or green pepper oil, peppermint oil, rosemary oil, strawberry oil, smoke oil, tobacco vanilla oil, vanilla oil, chocolate extract, anise extract, rose oil, linalool-containing oil, and combinations thereof. Example 35: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, wherein the salt-based composition comprises calcium chloride and / or magnesium chloride and at least 10% by weight of ethyl alcohol. Example 36: 33. The method of example 32, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, the droplets comprising greater than 4% by weight of calcium chloride and / or magnesium chloride. Example 37: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, the droplets having a mass median droplet diameter in the range of 9 microns to 10 microns. Example 38: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, the droplets having a mass median droplet diameter of about 10 microns with a standard deviation of less than 1 micron. Example 39: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, the droplets having a mass median droplet diameter in the range of 7 microns to 15 microns, with a standard deviation of less than 1 micron. Example 40: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, wherein a majority of the droplets have a droplet size between 9 microns and 10 microns in diameter. Example 41: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises generating an aerosol of droplets, wherein a majority of the droplets have a droplet size of about 9.5 microns in diameter. Example 42: 34. The method of any of Examples 31-33, further comprising the step of the subject inhaling an amount of aerosol droplets comprising between 0.5 mg and 4.0 mg of calcium chloride and / or magnesium chloride. Example 43: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises providing the aerosol of droplets to a free space where the aerosol of droplets is inhaled. Example 44: The method of example 43, further comprising the step of slowing the velocity of the aerosol relative to the velocity at which the aerosol leaves the dispenser, whereby the aerosol becomes relatively stationary. Example 45: 34. The method of any one of Examples 31-33, further comprising providing the aerosol within 12 inches to 1 inch of the subject's nose. Example 46: 34. The method of any one of Examples 31 to 33, further comprising providing the aerosol sufficiently far from the subject's nose so that the aerosol has zero or negligible net velocity, at least horizontally relative to the Earth. Example 47: 34. The method of any of Examples 31-33, wherein the step of generating an aerosol of droplets comprises providing the aerosol to an at least partially enclosed space in the form of a container, from which the aerosol is inhalable through an opening in the container. Example 48: 34. The method of any one of Examples 31 to 33, wherein the step of generating an aerosol of droplets comprises generating the aerosol for a predetermined period of time in response to an activation event, and ceasing the generating step after the predetermined period of time until a subsequent activation event. Example 49: 34. The method of any of Examples 31-33, wherein generating an aerosol of droplets comprises repeatedly generating the aerosol for predetermined periods of time, the predetermined periods being separated by periods during which generation of the aerosol stops so as to deliver multiple doses over a period of time. Example 50: 34. The method of any one of Examples 31 to 33, wherein generating an aerosol of droplets comprises providing the aerosol in a free space within a venue before and / or during an event. Example 51: The method described in Example 50, wherein providing the aerosol in a free space within a venue before and / or during an event includes providing the aerosol in a free space at an entrance to the venue. Example 52: The method described in Example 50, wherein providing the aerosol in a free space within a venue before and / or during an event includes providing the aerosol in a free space in a queue for the event through which subjects continuously pass, and the providing step is carried out continuously or periodically over an extended period of time during which access to the event is provided. Example 53: The method described in Example 52, wherein providing the aerosol in free space in a queue for the event through which subjects pass consecutively includes providing the aerosol at two or more locations along the length of the queue path used to access the event. Example 54: The method of example 52, wherein providing the aerosol in free space in a queue for the event through which subjects pass consecutively includes providing the aerosol along the entire length of at least a predetermined portion of a queue path used to access the event, the predetermined portion being long enough to provide a measured dose to each subject traversing the predetermined portion of the queue path at walking speed. Example 55: sequentially reading identification information from each subject passing through the aerosol; storing information representing each subject's passage of the aerosol; The method of Example 52, further comprising: Example 56: sequentially reading identification information from each subject passing through the aerosol via at least one machine-readable symbology reader, a radio frequency identification (RFID) interrogator, or via a facial recognition-based camera and processor-based computer system; storing information in at least one non-transitory processor-readable medium representing the amount of time each subject was exposed to the aerosol. The method of Example 54, further comprising: Example 57: 51. The method of example 50, wherein generating an aerosol of droplets comprises generating an aerosol of droplets wherein the salt-based composition is a purely sanitary composition. Example 58: 51. The method of example 50, wherein generating an aerosol of droplets comprises administering a therapeutically effective amount of the salt-based composition to the subject to generate an aerosol of droplets for suppressing viral shedding. Example 59: The method of Example 31, wherein the method of administering the formulation or composition to the nose, trachea, and main bronchi of a subject's respiratory tract comprises administering the salt-based composition to the nose of the subject while the subject is tilting their head back or in a reclined position that promotes post-nasal drip. Example 60: 60. The method of example 59, wherein administering the salt-based composition to the nose of the subject comprises administering the salt-based composition to the nose of the subject for 5 to 10 seconds while the subject's head is tilted. Example 61: 60. The method of Example 59, wherein administering the salt-based composition to the nose of the subject comprises administering the salt-based composition to the nose of the subject for 30 seconds or more while the subject is in a reclined position. Example 62: 1. A method for inhibiting exhalation of particles in the upper respiratory tract of a subject, comprising: generating an aerosol of droplets of a salt-based composition comprising calcium chloride and / or magnesium chloride, the droplets having a mass median droplet diameter in the range of about 7 microns to about 15 microns; administering the aerosol of droplets to airway mucosal mucus in the nose, trachea, and major bronchi of the subject, thereby suppressing the exhalation of particles in the upper respiratory tract of the subject. Example 63: 63. The method of example 62, wherein generating an aerosol of droplets comprises generating an aerosol of droplets comprising calcium chloride and / or magnesium chloride in water. Example 64: 64. The method of any one of Examples 62 or 63, wherein administering the aerosol of droplets comprises administering the aerosol of droplets while suspended in a stationary cloud. Example 65: 1. A delivery system operable to deliver a purely hygienic or antibacterial formulation or composition to the nose, trachea and main bronchi of a subject's respiratory tract, said delivery system comprising: a reservoir having at least one wall at least partially separating an interior of the reservoir from an exterior thereof, the reservoir having a port providing a fluid communication path between the interior of the reservoir and its exterior, the reservoir holding, at least in use, the hygienic or antibacterial formulation or composition comprising a quantity of water and at least calcium chloride and / or magnesium chloride dissolved in the water; at least one delivery device operable to cause the formation of an aerosol comprising readily soluble droplets having a mass median diameter range of about 7 microns to about 15 microns, the aerosol comprising at least calcium chloride dissolved in the quantity of water; A delivery system comprising: Example 66: The delivery system described in Example 65, wherein the at least one delivery device comprises at least one orifice having a size in the range of 3.5 microns to 7.5 microns, and at least one pump operable to dispense a jet from the at least one orifice. Example 67: the at least one delivery device comprising: At least one nebulizer delivery device, the at least one nebulizer delivery device comprising an actuator, the actuator controllably operable on an active agent medium to cause the formation of an aerosol comprising readily soluble droplets having a mass median diameter range of about 7 microns to about 15 microns, the aerosol comprising at least calcium chloride dissolved in the quantity of water. 66. The delivery system of Example 65, comprising: Example 68: The delivery system of Example 67, wherein the at least one nebulizer delivery device is a nebulizer and further comprises a respective control subsystem communicatively coupled to control the actuator. Example 69: The delivery system of Example 67, wherein the at least one nebulizer delivery device is a nebulizer including a mesh screen mounted for vibration, a microcontroller, and at least one of a piezoelectric transducer, a solenoid, or an electric motor drivingly coupled to vibrate the mesh screen along at least one axis in response to a signal from the microcontroller to dispense an aerosol. Example 70: The delivery system of Example 67, further comprising at least one switch or sensor communicatively connected to the microcontroller, the microcontroller operable to generate a signal that operates the actuator in response thereto. Example 71: The delivery system described in Example 67, further comprising at least one switch or sensor communicatively connected to the microcontroller and operable to generate a signal to cause the microcontroller to operate the actuator in response to the at least one nebulizer delivery device being tilted relative to a normal or upright position. Example 72: The delivery system of Example 67 further comprises at least one switch or sensor communicatively coupled to the microcontroller, responsive to the position or orientation of the container, and operable to generate a signal that causes the microcontroller to operate the actuator according to the orientation of the container. Example 73: 68. The delivery device of Example 67, wherein the at least one nebulizer delivery device is removably dockable to the reservoir. Example 74: a measured amount of calcium chloride and / or magnesium chloride; a container sized to receive a specified amount of water for dissolving the calcium chloride; Instructions A kit for suppressing exhalation of particles in the upper respiratory tract of a subject, comprising: Example 75: The kit of Example 74, wherein the amount of calcium chloride and / or magnesium chloride is itself in a sealed package. Example 76: Apart from the measured amount of calcium chloride, a measured amount of at least one of distilled water or sterile water, which is sealed in its own package. The kit of Example 74, further comprising: Example 77: 1. A method of administering a formulation or composition to the nose, trachea, and main bronchi of the respiratory tract of a subject, comprising: generating an aerosol of droplets in a space from which the aerosol is inhalable by the subject without application of force into the nose, trachea, and main bronchi of the respiratory tract of the subject; the aerosol of droplets comprises a salt-based composition comprising calcium chloride and / or magnesium chloride in water; The method of administering the formulation or composition to the nose, trachea, and main bronchi of the subject's respiratory tract is accomplished by spraying the salt-based composition into the subject's nose while the subject is tilting their head back or in a reclined position that promotes post-nasal drip. Example 78: 1. A composition of aerosol droplets comprising a salt-based composition, about 1% to about 5% by weight of calcium chloride and benzalkonium chloride preservative in water, or a sufficient amount of acid to lower the pH of the salt-based composition to about 2 to about 3; 1. A composition of aerosol droplets comprising a salt-based composition comprising: Example 79: The composition of example 78, wherein the salt-based composition further comprises magnesium chloride. Example 80: The composition of either Example 78 or Example 79, wherein the droplets have a mass median droplet diameter in the range of 7 microns to 15 microns. Example 81: The composition of example 80, wherein the majority of the droplets have a droplet size between 9 microns and 10 microns in diameter. Example 82: The composition of example 78, wherein the salt-based composition comprises a benzalkonium chloride preservative, and the benzalkonium chloride is present in an amount ranging from about 0.05% to about 0.2% by weight. Example 83: The composition of example 78, wherein the salt-based composition comprises the acid, and the acid is citric acid, hydrochloric acid, or a combination thereof. Example 84: The composition of Example 78, wherein the composition is in the form of a 20 mg to 30 mg dose. Example 85: The method of Example 84, wherein a dose of 20 mg to 30 mg of the formulation is administered intranasally to the subject.

[0165] Applicant hereby incorporates by reference U.S. Provisional Patent Application No. 62 / 687,970 filed June 21, 2018, U.S. Provisional Patent Application No. 62 / 628,395 filed April 3, 2018, U.S. Provisional Patent Application No. 62 / 556,974 filed September 11, 2017, U.S. Provisional Patent Application No. 62 / 727,123 filed September 5, 2018, U.S. Provisional Patent Application No. 6 / 122,673 filed September 5, 2018, U.S. Provisional Patent Application No. 63 / 048,421 filed July 6, 2020, U.S. Provisional Patent Application No. 63 / 121,448 filed December 23, 2020, U.S. Provisional Patent Application No. 7 / 139,401 filed December 31, 2020, 2020; and international patent application PCT / US2018 / 050250 (published as WO 2019 / 051403)

[0166] Adam P, Stiffman M, and Blake RL, Jr (1998) "Clinical trial of hypertonic saline nasal spray in subjects with colds or rhinosinusitis." Arch Fam Med 7(1), 39-43; Alp S, et al (2005) "Expression of beta-defensins 1 and 2 in nasal epithelial cells and alveolar macrophages in HIV-infected patients." Eur J Med Res 10(1), 1-6.; Bai, Y, et al (2020) Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA; Bastier (2015) "Nasal irrigation: from empiricism to evidence-based medicine"; Review Bunyan D, et al (2013) "Respiratory and facial protection: a critical review: a critical review of the recent literature." J Hosp "Infection." 85(3), 165-169; Calmet H, et al (2019) "Deposition of Nasal Spray Particles in the Human Nasal Cavity under Different Inhalation Conditions". PLOS ONE 14(9), e0221330; Choy et al (2020) Remdesivir "Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 T Replication In Vitro". Antiviral Research 178, 104786; Dellanno C, Vega Q, and Boesenberg D (2009) "Antiviral Activity of Common Household Disinfectants and Sanitizers against Murine Hepatitis Virus, a Potential Surrogate for SARS-CoV-2". American Journal of Infection Control 37(8), 649-652;Edwards DA, et al (2004) "Inhalation to Mitigate Exhaled Bioaerosols".National Academy of Sciences 101(50), 17383-17388;Fauci AS, Lane HC, and Redfield RR (2020) "Navigating Covid-19 - Uncharted Steps.New England Journal of Medicine 382 (13), 1268-1269; Fulcher ML, et al (2005) "Highly Differentiated Human Airway Epithelial Cell Cultures," (ed. Picot J) "Human Cell Culture Protocols." METHODS IN MOLECULAR MEDICINETM, VOL 107. HUMANA PRESS, 183-206. GELLER C, VARBANOV M, Duval R (2012) "Human coronaviruses: insights into environmental resistance and their implications for the development of new disinfection strategies." Viruses 4 (11), 3044-3068; Head, K, Snidvongs, K, Glew, S., Scadding, G., Schiller, A., Philpot, C and C Hopkins (2018). "Saline irrigation for allergic rhinitis." Cochrane Database Syst Rev. CD01259; Hou, YJ et al (2020) "Reverse genetics of SARS-CoV-2 reveals diverse infection gradients in the respiratory tract". Cell 182, 1-18; Kim J, et al (2018) "Human β-defensin 2 plays a regulatory role in innate antiviral immunity and has the ability to enhance the induction of antigen-specific immunity". Virology Journal 15(1); Krisanaprakornkit S, Jotikasthira D, Dale BA (2003) "Intracellular calcium in signaling of human β-defensin-2 expression in oral epithelial cells". J Dent Res 82(11), 877-82; Lescure, FX, et al (2020) "Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases"; Leung NHL, et al (2020) "Respiratory virus shedding in exhaled breath and the effectiveness of face masks".NATURE MEDICINE; NGAOSUWANKUL N, ET AL (2010) Influenza A viral load in respiratory specimens collected from patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. Virology Journal 7(1), 75. Ramalingam S, et al (2018) "Chloride ions enhance antiviral innate immune responses in non-myeloid cells via increased intracellular hypochlorous acid levels." Scientific Reports 8(1); Ramalingam S, et al (2019) "A pilot, open-label, randomized controlled trial of hypertonic saline nasal irrigation and gargle for the common cold." Scientific Reports 9(1); Schmittgen TD and Livak KJ (2008) "Analysis of real-time PCR data by the comparative C(T) method." Nat Protoc 3(6), 1101-8; Slapak I et al (2008) "Efficacy of isotonic nasal irrigation (seawater) in the treatment and prevention of rhinitis in children." Arch Otolaryngol Head Neck Surg 134(1), 67; Speir RW (1961) "The effect of some inorganic salts on the infectivity of mengovirus." Proceedings of the Society for Experimental Biology and Medicine 106(2), 402-404; Sweet C and Smith H (1980) "Pathogenesis of influenza viruses." Microbiol Rev 44(2), 303-30; Van Doremalen N, et al (2020) "Aerosol and surface stability of SARS-CoV-2 compared with SARS-CoV-1." New England Journal of Medicine 382, ​​1564-1567; Wang J, and Du G (2020) ["COVID-19 can be transmitted through aerosols."Irish Journal of Medical Science (1971-); Watanabe W, et al (2007) "Why does saline inoculation change what we spit out?" J Colloid Interface Sci 307(1), 71-8; WHO guidelines on hand hygiene in health care: the first global patient safety challenge. Clean care is safer care." Geneva: World Health Organization; 2009. "Historical perspectives on hand hygiene in health care." Available: https: / / www.ncbi.nlm.nih.gov / books / NBK144018; Zhang, PR Et al(2020) "Identifying airborne transmission as a major route of spread of COVID-19". PNAS, 1-7; Zhao H, et al (2016) "Novel peptides with potent and broad-spectrum antiviral activity against multiple respiratory viruses." Scientific Reports 6(1), 22008; Zou L et al (2020) "SARS-CoV-2 viral load in upper respiratory tract specimens from infected patients." New England Journal of Medicine 382(12), 1177-1179. https: / / www.ncbi.nlm.nih.gov / books / NBK144018 / , Zhang, PR et al. (2020) "Identifying airborne transmission as the primary route of spread of COVID-19." PNAS, 1-7; Zhao H, et al (2016) "Novel peptides with potent and broad-spectrum antiviral activity against multiple respiratory viruses." Scientific Reports 6(1), 22008; Zou L, et al (2020) "SARS-CoV-2 viral load in upper respiratory tract specimens from infected patients." New England Journal of Medicine 382(12), 1177-1179.

[0167] The various embodiments described above can be combined to provide further embodiments. These and other modifications can be made to the embodiments in light of the above detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments, along with the full range of equivalents to which such claims are entitled. Accordingly, the claims are not limited by this disclosure.

Claims

1. CaCl 2 and MgCl 2 and an aerosol generator that produces droplets of the sterile solution that are less than 7-15 microns in diameter.

2. The salt is CaCl 2 The apparatus of claim 1 ,

3. The salt is MgCl 2 2. The apparatus of claim 1 ,

4. The salt is CaCl 2 and MgCl 2 2. The device of claim 1, wherein the mixture is

5. The device of claim 3, wherein the salt is present in the sterilizing solution at a concentration of 4% to 5%.